split-banner-image

MASTECTOMY RECOVERY

Learn what to expect during mastectomy recovery, including healing timelines, recovery tips, emotional support and when to contact your doctor.

A mastectomy is a major breast cancer surgery that involves removing one or both breasts to treat or reduce the risk of developing breast cancer. While it is a common and often effective treatment, the decision to have a mastectomy can feel overwhelming.  

Many people, including men and women, describe the lead-up to surgery as one of the most emotionally and practically challenging periods of their breast cancer journey.  

Emotionally, preparing for a mastectomy can bring up feelings of fear, uncertainty, grief, and anxiety. You may be processing the shock of a recent diagnosis, thinking about how your body will change, or wondering how you’ll cope physically and emotionally afterwards. It’s normal to experience concerns about body image, intimacy, sexuality, and identity – alongside worries about the surgery itself.  

Practically, there’s a lot to manage as well. From organising time off work and understanding your surgical options, to preparing your home environment, arranging support, and navigating pre-operative appointments, the planning phase can feel like a full-time job. Many people also find themselves juggling childcare, family responsibilities, financial considerations, and coordinating help for the first few weeks at home.  

Understanding what mastectomy recovery involves – physically, emotionally, and practically – can help you feel more prepared and supported. This article walks you through what to expect before and after surgery, tips for navigating recovery, and insights from people who’ve been there. 

If you’re still deciding about surgery, read our guide explaining types of mastectomy and reconstruction options. 

Mastectomy types and their impact on recovery 

Single mastectomy recovery

Single mastectomy recovery is generally more straightforward than a double mastectomy because only one side of the chest needs to heal. This means less discomfort, fewer limitations in arm movement, and a quicker return to daily tasks.    

Double mastectomy recovery

With a double mastectomy, because both sides of the chest are healing at once, women typically experience more pain, tightness, and fatigue during the early weeks. Arm mobility can be significantly reduced, making everyday activities, like getting out of bed, reaching overhead, or dressing, more challenging at first but many women regain strength and mobility steadily with guided exercises and appropriate follow-up care.   

Mastectomy recovery timeline: what to expect 

Recovery happens in phases, and no two people heal in the same way. The below timeframes are general guidelines only. 

0–2 weeks: Immediate post-op 

  • Hospital stay of 1–2 days 
  • Some level of pain is expected, as well as swelling, bruising, tightness and limited arm movement 
  • Surgical drains may be in place 
  • No heavy lifting until advised by your doctor 
  • Rest, gentle walking, and wound care are prioritised 
  • Wear a breast binder or post-surgical bra 
  • Watch for signs of infection, including redness, increased swelling, warmth, pus or fever 

2–6 weeks: Short-term healing 

  • Gradual return to everyday activities 
  • Increased arm mobility 
  • Fatigue and emotional shifts are common 
  • Follow your surgeon’s guidance on driving and lifting 

6 weeks+: Long-term recovery and lifestyle adjustments 

  • Most women resume daily life and work (as appropriate) 
  • Scar healing, ongoing physiotherapy, and emotional adjustment 
  • Those with reconstruction may take longer to fully recover 
  • Fatigue can persist for several months 

“What I wish I knew before mastectomy”: real stories & reflections

Many women say the emotional side of recovery can be just as challenging as the physical. Some reflections include:  

“Recovery is not linear. It can feel like a roller coaster, with ups and downs along the way, and it will look different for everyone both physically and emotionally. Try not to compare your recovery to anyone else’s, be kind to yourself, and allow yourself to take the time you need to heal”- Katrina  

“Look into post operative physiotherapy options early, rather than waiting for issues to arise. Taking an active role in your recovery asking about safe exercise, mobility, and long-term function can make a meaningful difference. If something doesn’t feel right post op speak up.” – Katrina  

“I wish I knew before my mastectomy not to get caught up with buying multiple bras, in built bra tank tops and swimmers and then an array of pillows to assist post surgery. It all adds up financially and I know everyone is different, but for me it wasn’t necessary. It was panic buying in my case.” – Kate  

Emotional and mental preparation

It’s normal to feel anxious, uncertain, or overwhelmed while preparing for a mastectomy. Many women find this time emotionally challenging as they process how surgery may change their body and what it might mean for their sexuality and identity. 

Concerns about appearance, recovery, and what life will look like afterwards can all contribute to fear about life post mastectomy. These feelings are common and understandable. You should discuss any concerns that you have about your planned surgery with your treatment team. 

What to do before surgery

The most important thing before a mastectomy is to make sure that you understand the planned surgery, reconstruction options and likely recovery. Consider keeping a notebook with a list of questions to make sure you don’t forget to ask anything. 

There are also practical preparations that can help make the experience of surgery and recovery easier. Taking time to organise your home and arrange support can mean you head into surgery feeling more informed and in control and make the first weeks of recovery much easier.

Factors that affect mastectomy recovery

Every woman’s recovery is unique, and several medical and personal factors influence how quickly and comfortably you heal. These can affect your physical recovery timeline, your emotional wellbeing, and the type of support you may need after surgery. 

Why breast cancer stage affects mastectomy recovery

Recovery can vary based on breast cancer stage because: 

  • In early breast cancer when there is an emphasis on prompt treatment, emotional recovery may be more complex, especially if the cancer is aggressive or treatment decisions were made quickly. 
  • Locally advanced cancers may require more extensive surgery to the breast and axilla, such as an axillary clearance, which increases pain, swelling, and the risk of lymphoedema. 
  • Reconstruction timing may be influenced by stage: women needing radiation post-surgery may have delayed reconstruction, affecting both short and long-term recovery timelines. 
  • People with advanced cancer may also be undergoing chemotherapy or radiation therapy or have other cancer related symptoms which can slow wound healing and prolong fatigue. 
  • Other factors that influence recovery: 
    • Age and general health: Younger, fitter women often recover faster. Pre-existing conditions (diabetes, heart conditions, obesity) and cigarette smoking/vaping may slow healing. 
    • Type of mastectomy: Single, double, skin-sparing, nipple-sparing 
    • Axillary surgery: whether a sentinel lymph node biopsy or axillary clearance are performed. 
    • Reconstruction choices: Immediate reconstruction, especially flap surgery, increases initial recovery time.
      Complications: Infections, seromas, lymphoedema and cording (or axillary web syndrome) can prolong recovery. 
    • Seroma: pockets of fluid can develop in the immediate weeks after surgery. This can feel like a soft or hard swelling under the skin. Seromas often disappear by themselves over time but can sometimes need draining. 
    • Lymphoedema: a build-up of lymph fluid in the tissues because the lymphatic system is damaged, blocked, or not working as well as it should. This extra fluid causes swelling, heaviness, tightness, and discomfort often in the chest wall or arm. Unlike a seroma, it cannot be drained. 
    • Cording (axillary web syndrome): rope-like cords that appear under the skin of your inner arm. This can feel painful or tight and make it hard to lift your arm or straighten your elbow fully. 
    • Emotional health: Anxiety, trauma, or body image concerns may affect overall wellbeing and pace of recovery. 

Skin-sparing and nipple-sparing recovery

Physical recovery after a skin-sparing or nipple-sparing mastectomy is generally similar to a traditional mastectomy, though the preserved skin or nipple may need extra care as it heals. Emotionally, some women find the process easier because more of their natural breast contour is maintained, which can help with body image and adjustment. 

Practical tips for a smoother recovery

The fastest way to recover from a mastectomy is to follow the guidance of your treatment team, as they understand the specific needs of your surgery and overall health. While every woman’s recovery timeline is different, adopting healthy habits can support your healing, improve comfort, and help you regain strength more steadily. Many patients find that small, consistent actions make a meaningful difference in how they feel day to day. 

These additional habits contribute to a quicker recovery: 

  • Take medications as prescribed 
  • Practice deep breathing and coughing 
  • Sleep slightly upright on your back for the first few weeks to reduce pain and pressure on wounds and drains as well as reduce swelling  
  • Keep wound and drain sites clean 
  • Start gentle physiotherapy exercises as instructed 
  • Maintain hydration and balanced nutrition 
  • Reach out to your treatment team with any questions or if you need support 

Things you need after a mastectomy

Having the right items on hand can make your recovery more comfortable and help you move around with greater ease in the first few weeks after surgery. These practical tools and sources of support can reduce strain on your body, help manage pain or swelling, and provide emotional comfort during a challenging time. 

Your treatment team will provide you a list of items required to support your journey that is personalised to your situation.

Some additional items that may help physically or emotionally include: 

  • Comfort cushions or post-surgical cushions (you may be provided with a cushion whilst in hospital) 
  • Front-button shirts 
  • Soft wire-free bra. Front opening bras can be easier to use with limited arm mobility (you may be provided with a bra whilst in hospital) 
  • Drain care kit including a drain bag and cleaning supplies 
  • A journal for emotional processing 
  • Support from friends, family, or professionals.  

Home care after mastectomy

Caring for yourself at home is an important part of healing after a mastectomy. Establishing a simple routine for wound care, rest, and gradual movement can help prevent complications and support a smoother recovery. Your treatment team will give you specific instructions, but these are the common elements of home care: 

  • Regular wound checks 
  • Drain management 
  • Dressing changes 
  • Avoiding strenuous activity 
  • Good hygiene and rest 

When can you resume normal activities? 

Disclaimer: This information is general in nature and not a substitute for medical advice. Always consult your GP or treating specialists for guidance tailored to your own breast cancer diagnosis and recovery. 

Timelines vary widely from person to person, but these general guidelines can help manage expectations: 

  • Lifting your arms: It is ideal to limit overhead arm movement for up to 2 weeks post operatively, or longer if drains remain in place. Patients should also avoid lifting anything over 2kg for up to 6 weeks depending on your surgery. Always check with your surgeon for specific advice for your situation. 
  • Driving: Typically allowed after 2–3 weeks, once you can safely shoulder-check, turn the wheel, and are no longer taking strong pain medication. This is usually after your post-operative follow up appointment with your surgeon. It is important to feel confident before returning to driving – if you feel anxious about driving speak to your treatment team. 
  • Returning to work: Many women return to light duties between 4–6 weeks, but this is very dependent on the type of surgery and the type of work performed. Physically demanding jobs may require significantly more time off. 
  • Fatigue: Fatigue is very common after a mastectomy and can persist for several months which can affect when women feel ‘back to normal’ 

Personal variability and the importance of medical clearance 

Recovery looks different for everyone. Factors like age, overall health, the type of mastectomy, lymph node removal, and whether reconstruction was performed all affect how quickly you can return to normal activities. Some women feel ready within a few weeks, while others need several months due to pain, fatigue, or limited mobility.  

Because of these differences, medical clearance is advised before resuming activities such as lifting, driving, or strenuous movement. Your treatment team will assess wound healing, drain removal, shoulder mobility, and any signs of complications to determine what’s safe for you.  

Even if you feel ready, pushing too hard too soon can lead to setbacks. Follow-up appointments and physiotherapy help ensure you return to daily routines at a pace that protects your healing and long-term wellbeing. 

Emotional recovery

Emotional recovery is a real part of healing after a mastectomy, and it’s completely normal for it to feel just as challenging – sometimes more so – than the physical recovery. It can also take much longer than the physical healing and vary widely between individuals. 

Patients who have a mastectomy may experience sadness at the loss of a breast. They may also experience sexuality and identity shifts, as well as fears about recurrence.  

When possible, immediate breast reconstruction is thought to lead to improved psychological, emotional and social outcomes, as the patient wakes from their surgery  

with a new breast. But even with reconstruction it usually takes 3–12 months for women to feel better about their body image. 

Whilst it can be confronting, it is important to look at your chest after your surgery. This allows you to monitor your healing and detect any complications like seromas or infections. It also helps you adjust to your new body image. If you are anxious about seeing your new chest after your surgery, you should discuss this with your treatment team. 

It is important to discuss any difficulties with emotional recovery with your treatment team, and to consider engaging with counselling or psychology and peer support groups. 

Emotional and Mental Support options

Support is available in many forms, including counselling or psychology services to help you process emotions, peer support groups where you can connect with others who’ve had similar experiences, and breast care nurses who can provide guidance, reassurance, and practical advice throughout your treatment and recovery. Self-care strategies like eating well, resting adequately, exercising and practicing mindfulness and deep breathing exercises for if you feel anxious are also important to implement. 

You can read more about mental health and breast cancersexual health after breast cancer and other useful resources on our website.   

When to contact your doctor

It is important to monitor your symptoms closely after surgery, as early signs of complications can sometimes be subtle. Paying attention to changes in your body and contacting your treatment team promptly can help prevent small issues from becoming more serious. Most patients have follow up with their surgeon several weeks after their surgery, however you should seek additional medical advice if you notice: 

  • Redness, heat, swelling or pus around the wound 
  • Fever or chills 
  • Feeling generally unwell 
  • Sudden fluid build-up (possible seroma) 
  • Severe pain not controlled by medication 
  • Restricted shoulder or elbow movement 
  • Issues with drains 
  • Attend all follow-up appointments to stay on track with your recovery

Returning to work after mastectomy

Returning to work after a mastectomy is an important milestone for many women, but the timing can vary widely depending on the type of surgery, your overall health, your job demands, and how you’re feeling physically and emotionally. Most women return to work somewhere between 4–8 weeks after surgery, although some may require longer – especially after a double mastectomy or reconstruction. 

Physical readiness:

Before going back to work, asses your physical readiness and whether you can comfortably manage the physical demands of your role. Some questions you can ask yourself are: 

  • Can you sit, stand, or move comfortably for extended periods? Prolonged sitting or repetitive arm movements can feel tiring or uncomfortable in early recovery. 
  • Is your arm and shoulder mobility adequate? Many jobs require reaching, lifting, or turning – activities that may still be restricted. 
  • Are you still experiencing significant pain or fatigue? Fatigue can linger for weeks and even months, especially if you’re also undergoing reconstruction or other treatments. 
  • Has your treatment team cleared you? Your surgeon or breast care nurse will assess wound healing, scar tissue, and your overall movement before advising whether it’s safe to return. 

Women with physically demanding jobs (e.g., nursing, childcare, hospitality, retail, or roles involving lifting) may need a longer recovery period or modified duties. 

Emotional Readiness:

Going back to work is not just a physical decision – it’s also an emotional one. It’s very important to assess your emotional readiness. Many women experience a range of feelings, including: 

  • Anxiety about how colleagues will respond 
  • Concerns about your new appearance, especially after going flat and even after reconstruction 
  • Reduced confidence or difficulty concentrating 
  • Feeling overwhelmed or fatigued by social or sensory environments 

It’s helpful to ask yourself: 

  • Do I feel emotionally supported and ready for social interaction? 
  • Can I manage stress without feeling overwhelmed? 
  • Do I need more time to rest or adjust before returning to routine? 

Emotional readiness can be just as important as physical readiness, and it’s okay to request more time if you need it. 

Tips for a phased return to work

A gradual return can help you rebuild strength, confidence, and stamina without overwhelming yourself. Here are some options to consider: 

Reduced hours or part-time return (e.g., mornings only for the first 1–2 weeks) 

  • Alternating work-from-home and in-office days, if possible 
  • Light duties that avoid lifting, overhead movement, or strenuous activity 
  • Scheduled rest breaks to manage fatigue 
  • Adjusting your workstation for better posture and comfort (e.g., ergonomic chair, monitor height adjustments) 

Many women find that easing back into their routine helps prevent setbacks and supports long-term recovery. 

Communicating with your employer

Clear and proactive communication can make your return much smoother. Here are some considerations: 

  • Letting your employer know about your expected timeline early, even if it may change 
  • Requesting adjustments based on your treatment team’s recommendations 
  • Discussing flexible arrangements, such as a phased return or modified duties 
  • Providing medical certificates or recovery plans if required 
  • Setting boundaries, such as not lifting heavy items or avoiding tasks that strain your upper body 

If you’re unsure how much detail to share, focus on the functional impact rather than the personal specifics. For example: 

“My doctor has advised that I avoid lifting and overhead reaching for the next few weeks. I may need modified duties until I regain full mobility.” 

Many workplaces are supportive when they understand what you need and why. 

Final tips: what patients say helped the most

Many women say that accepting help early, wearing loose clothing, and keeping a simple rest routine made recovery easier. Gentle movement can ease stiffness and connecting with others who’ve been through a mastectomy often provides valuable reassurance and practical advice.  

If you’d like to support research that improves breast cancer treatment options, please consider donating to Breast Cancer Trials. 

Frequently Asked Questions

How long does it take to recover from a mastectomy?

Recovery after a mastectomy happens gradually over several weeks and months, and the timeline can vary depending on the type of surgery and whether reconstruction is involved.  

Most women spend 1–2 days in hospital, with the first 1–2 weeks focused on rest, managing pain and drains, and gently improving mobility. By 2–6 weeks, swelling and discomfort usually lessen, and many women feel ready to resume light activities, including driving or returning to work in non-physical roles.  

Full recovery from a mastectomy can take up to 3 months.  especially after flap surgery-as  there are additional surgical sites and more complex healing.  

Your recovery may be faster or slower depending on factors such as age, general health, whether lymph nodes were removed, and any complications or additional treatments like chemotherapy or radiation.  

Can you live a normal life after a mastectomy?

Yes. Most women go on to live full, active, and healthy lives after a mastectomy. Once recovery is complete, many return to work, exercise, and their usual routines. Long-term outcomes are generally very positive – women often regain strength and mobility,  and adapt well to body changes with support, physiotherapy, and self-care. While some changes in sensation or scarring may remain, these rarely prevent a fulfilling, normal life.  

How does a woman feel after a mastectomy?

Feelings range from grief and numbness to relief and empowerment. Persisting physical sensations like tightness or numbness are common. Counselling and support groups can help process these very normal feelings.  

What are the restrictions after mastectomy?

Common restrictions include no heavy lifting, driving, or strenuous activity for at least several weeks. Your surgeon will give specific guidance based on your surgery and individual recovery prospects such as age and health.  

What special items are required by mastectomy patients?

Items such as mastectomy bras, drain management kits and comfort cushions can significantly improve comfort and recovery by reducing pressure on healing tissues, supporting proper posture, keeping surgical drains secure, and helping you rest in positions that minimise pain and swelling. These small adjustments can make everyday movements easier and promote smoother, safer healing.  

How long do I have to sleep sitting up after a mastectomy?

Most women need to sleep sitting up or at an incline or on their side for 1–2 weeks after a mastectomy. This position helps reduce swelling, protects surgical sites and drains, and makes it easier to get in and out of bed without straining the chest or arms. Using supportive items such as pillows or a recliner chair can make resting more comfortable and promote smoother healing. You can gradually transition to a flatter position once your surgeon confirms it’s safe.  

How traumatic is a mastectomy?

A mastectomy can be both physically and emotionally challenging. Pain, tightness, fatigue, and changes in sensation are common early on and can feel overwhelming, but these usually improve over time. Emotionally, many women experience grief, anxiety, or difficulty adjusting to changes in appearance, which are normal responses.  

Coping strategies such as gentle movement, relaxation, talking with loved ones, and connecting with others who’ve had a mastectomy can help. Professional support can also be valuable. With time, support, and self-care, most women adjust well and regain confidence. 

Join Our Free Q&A Webinars

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Join our FREE Q&A webinars, where we cover important topics including whether more young women are being diagnosed with breast cancer.

Stay Connected with Breast Cancer Trials

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Sign up to our researcher’s newsletter via the form below to stay up to date.

Name(Required)

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

split-banner-image

MASTECTOMY: TYPES AND RECONSTRUCTION

Learn about mastectomy surgery, including types of mastectomy, when it is recommended, and reconstruction options for breast cancer treatment.

What is a mastectomy?

A mastectomy is a surgical procedure to remove the entire breast, usually performed to treat breast cancer or substantially reduce the risk of developing it. Patients may choose or need to have a mastectomy for several reasons, including: 

  • Treating early and locally advanced breast cancer that is still localised to the breast and surrounding lymph nodes 
  • Reducing risk in people with high-risk genetic mutations that predispose to developing breast cancer (e.g., TP53, BRCA1 and BRCA2) 
  • Treating breast cancer that has recurred in the breast after previous treatment 
  • Rarely, people with advanced breast cancer that has spread beyond the breast and surrounding lymph nodes may also have a mastectomy to manage problems such as chronic cancer wounds 

Mastectomy vs. lumpectomy: what’s the difference?

The two main surgical options for managing breast cancer are mastectomy and lumpectomy, also known as a partial mastectomy or breast conserving surgery. 

  • Mastectomy removes the whole breast. 
  • Lumpectomy, or breast conserving surgery, removes only the tumour and a small margin of surrounding normal breast tissue. It usually requires post operative radiotherapy to treat the remaining breast tissue. 
  • The right option depends on cancer stage, tumour size, genetic risk, and personal preference. 

When is a mastectomy recommended

A mastectomy can be recommended for a range of reasons including: 

  • The tumour is large and there will be little normal breast tissue left after removal of the cancer, resulting in breasts that are significantly different sizes.  
  • There are multiple tumours in different areas of the breast and removal of all the tumours would result in breasts that are significantly different shapes and sizes. 
  • There is a large area of ductal carcinoma in situ (DCIS) that needs to be removed to reduce the risk of developing breast cancer 
  • The person has a high-risk genetic mutation that predisposes to developing breast cancer (e.g., BRCA1/2) 
  • They prefer mastectomy to reduce future breast cancer risk 
  • They wish to avoid post mastectomy radiotherapy to the breast (noting this may still sometimes be required depending on tumour factors) 

Many women with early-stage breast cancer (stage 0-II) can choose between lumpectomy and mastectomy and still have optimal treatment of their breast cancer. This is often paired with a sentinel lymph node biopsy which involves removal of only the first draining lymph nodes in the axilla (armpit), which is a lesser surgery with quicker recovery time than an axillary clearance.  

Women with locally advanced breast cancer (stage III) may be recommended to have a mastectomy, especially if the tumour is larger and not suitable for lumpectomy. These women often have cancer that has spread to multiple lymph nodes and requires removal of all the lymph nodes in the armpit, called an axillary clearance. An axillary clearance is a more extensive surgery than a sentinel lymph node biopsy that can increase the risk of complications like lymphoedema and prolong recovery time. 

Inflammatory breast cancer is a rare, aggressive type of breast cancer that doesn’t present as a lump but instead causes the breast to be red, swollen and tender due to cancer cells blocking lymph vessels in the skin. This is ideally treated with pre-operative chemotherapy, followed by a mastectomy to ensure that the entirety of the cancer is removed.  

risk-reducing mastectomy is preventative (prophylactic) mastectomy due to high genetic risk or a strong family history of breast cancer.  This means it is performed because of the risk of breast cancer, not because a woman has breast cancer. Recovery may be physically easier because lymph nodes are typically not removed and there are no cancer-related symptoms to manage. 

Men and mastectomies

Men can also be diagnosed with breast cancer, which is commonly treated with a mastectomy as they have less breast tissue than women, meaning a lumpectomy may not be possible. Although breast cancer is less common in men, the physical and emotional impact of surgery can be just as significant. Men may face unique challenges, including delayed diagnosis, feelings of isolation, or a lack of awareness that breast cancer can affect them. Recovery after a mastectomy involves both physical healing and emotional adjustment, and men benefit from the same supports as women – clear information, medical guidance, and access to counselling or peer support. 

Who can I talk to about my treatment options? 

Your breast surgeon, breast care nurse, oncologist, or GP can guide you through benefits and risks, helping you make decisions aligned with your goals and values. 

 Types of mastectomy

The type of mastectomy you have can significantly influence your physical healing, emotional adjustment, and overall recovery after mastectomy. Each surgical option has its own benefits, considerations, and timelines for getting back to everyday life. Understanding these differences can help you prepare for the days, weeks, and months following your operation. 

Single vs. double mastectomy 

Single mastectomy

A single mastectomy involves removing one breast. This is usually all that is required for treatment of breast cancer, particularly if there is a low level of concern regarding development of cancer in the remaining breast. 

Double mastectomy

A double mastectomy removes both breasts and results in a longer and more demanding recovery. This usually occurs because of cancer in one breast and significant concerns about developing cancer in the other breast. Women can have breast cancer in both breasts at the same time, but it is rare. 

Emotionally, some women find reassurance in removing both breasts, especially if they are at higher genetic risk, while others may need more time to adjust to the changes in their body. 

Breast reconstruction options: with or without breast reconstruction

Your recovery will also vary depending on whether you choose reconstruction, the type of reconstruction performed and the timing of reconstruction. 

No breast reconstruction (“going flat”)

No breast reconstruction, also known as flat closure and “going flat”, often results in: 

  • A shorter operation 
  • Fewer surgical sites (incisions) 
  • A generally quicker recovery from mastectomy 
  • Fewer risks related to implants or flap surgery 
  •  Emotional recovery may take time as you adjust to a changed chest shape 

Decisions to consider: reconstruction vs going flat 

Choosing between reconstruction and going flat is a personal decision shaped by lifestyle, body image, and what feels right for you. Going flat offers a simpler surgery and recovery, which some women prefer, though adjusting to a flat chest can take time emotionally. 

Reconstruction can help restore breast shape and support body confidence for some, but it usually involves more extensive surgery and a longer healing process. Speaking with your surgeon, GP or breast care nurse can help you understand which option best aligns with your goals and comfort. 

Women who choose to ‘go flat’ also have non-surgical options including breast prostheses to recreate the shape of the breast without reconstruction. Prostheses are worn inside specialised bras and even swimwear and come in a range of sizes and weights that can be customised to the woman. There are government subsidies towards the cost of prostheses. 

Types of breast cancer reconstruction

There are 2 main types of reconstruction options, implant-based reconstruction and autologous flap reconstruction: 

  • Implant-based reconstruction (using silicone or saline implants) 
  • Autologous flap reconstruction (using tissue from another area of the body, such as the abdomen, back, or thighs) 

Implant based reconstruction can sometimes require a tissue expander which is a temporary device placed under the chest muscle or skin that is gradually filled with saline or air to allow the tissue to stretch prior to insertion of the permanent implant. 

Flap reconstruction has a longer recovery time as this surgery involves removing tissue from a separate part of the body (e.g abdomen in a DIEP flap) and attaching it to the chest wall to create the new breast shape.  This is more complicated surgery which can involve additional drains and more complex wound care, extend hospital stays, and restrict activity for several weeks. 

Single verses double reconstruction

Recovery time for bilateral reconstruction after double mastectomy is typically longer than going flat or having a single reconstruction after mastectomy on one side only. This is because surgery is required to both sides of the chest which means more time needed for healing and return to normal mobility and function. 

Immediate breast reconstruction 

Immediate reconstruction is performed during the same surgery as your mastectomy. Whilst this means that both the mastectomy and reconstruction are performed in the one surgery, it increases surgery time which may not be safe for patients with poorer general health. Immediate reconstruction also increases healing time which is not always ideal for more aggressive cancers that require treatment with post-operative chemotherapy. Some breast cancers also require post-operative radiation treatment which is preferrable to give prior to reconstruction.

Delayed reconstruction

Some women choose reconstruction months or years later. 

  • A shorter initial mastectomy recovery period  
  • More time to consider reconstruction options  
  • Flexibility if further treatment (like radiation) is needed 

Skin-sparing and nipple-sparing mastectomies 

Skin-sparing and nipple-sparing mastectomies are specialised surgical techniques designed to preserve as much of the breast’s natural appearance as possible. 

  • Skin-sparing mastectomy removes the breast tissue but keeps most of the overlying breast skin. 
  • Nipple-sparing mastectomy goes a step further by also preserving the nipple and areola, if it is safe to do so based on the location and type of cancer. 

These approaches are often used when a woman chooses immediate reconstruction because the preserved skin and sometimes the nipple, provides a natural envelope for an implant or flap, resulting in a more natural-looking outcome. 

Patient perspectives: deciding on a mastectomy

“Don’t be afraid to ask questions even the ones that feel small or repetitive. Appointments can be overwhelming, and it’s easy to forget what you wanted to ask once you’re in the room. Writing a list beforehand and taking it with you can be incredibly helpful. If possible, bring someone along to your appointment. These conversations can be emotionally charged, and having another person there to listen, absorb the information, and help relay it back to you later when you have the mental space can make a difference. Your medical team is there to support you, and advocating for yourself isn’t being difficult; it’s being informed.”– Katrina 

“I wish I knew before my mastectomy not to get caught up with buying multiple bras, in built bra tank tops and swimmers and then an array of pillows to assist post surgery. It all adds up financially and I know everyone is different, but for me it wasn’t necessary. It was panic buying in my case”. – Kate 

“After two years, I had a breast reconstruction. This was the best decision. Not only did the reconstruction make me feel physically whole again, it also improved my self-confidence and emotional wellbeing. I had completely underestimated how much a reconstruction would help me heal mentally and emotionally. So, with the benefit of hindsight, I would have planned my reconstruction as early as practical.” – Merryn 

Read Merryn’s full story here. 

I wish I knew before my mastectomy that I didn’t have to rush the decision about reconstruction. And I did feel that it was a rushed decision. It’s difficult making that decision about reconstruction when you have no hair, feeling like a drugged up alien and when you’re exhausted and emotional. I found lots of resources supporting reconstruction but little about what it’s like to either wait after all treatment is completed before making a decision or about being flat permanently. I knew what the scarring would look like and a discussion about external prosthesis but little about the emotional aspect of being flat. And that’s what I needed to know, how other women dealt with the emotional side.  Kate  

These stories highlight the importance of preparing for physical, emotional, and lifestyle changes. 

Sources:

https://www.bcna.org.au/resources/articles/breast-cancer-in-men

https://nbcf.org.au/about-breast-cancer/further-information-on-breast-cancer/breast-cancer-in-men/

https://www.cancer.org.au/types-of-cancer/breast-cancer/breast-cancer-in-men

Join Our Free Q&A Webinars

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Join our FREE Q&A webinars, where we cover important topics including whether more young women are being diagnosed with breast cancer.

Stay Connected with Breast Cancer Trials

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Sign up to our researcher’s newsletter via the form below to stay up to date.

Name(Required)

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

split-banner-image

CHEMOTHERAPY DURING PREGNANCY AND BREAST CANCER

Can you have chemotherapy while pregnant? Learn what Australian guidelines say about breast cancer treatment during pregnancy and risks to baby. 

Being diagnosed with breast cancer during pregnancy, or gestational breast cancer, can feel overwhelming, raising many urgent questions about treatment and the health of your baby. One of the most common concerns is whether chemotherapy during pregnancy is possible or safe. 

The reassuring news is that treatment decisions are carefully guided by medical evidence and Australian clinical guidelines. In many cases, chemotherapy can still be given during pregnancy, particularly in the later stages. When treating breast cancer in pregnancy, both cancer specialists and obstetric teams work closely to protect the health of both mother and baby. Understanding how chemotherapy is used during pregnancy can help you feel more informed and supported when making decisions about your care.  

Breast Cancer During Pregnancy

Although uncommon, breast cancer during pregnancy does occur. It affects 15-25 per 100,000 pregnancies worldwide, and the number of cases is increasing as more women delay pregnancy until their 30s and 40s. 

During pregnancy, the body produces higher levels of hormones such as oestrogen, which stimulate breast development to allow breast feeding. The mother’s immune system also changes to allow the growth of the baby. These and other factors can lead to the development of breast cancer during pregnancy. Normal breast changes during pregnancy – such as swelling, tenderness and increased breast density – can also make cancer harder to detect early. As a result, some women may be diagnosed at a slightly later stage. 

Even when diagnosed during pregnancy, many women can still receive effective cancer treatment. In some situations, chemotherapy may be recommended as part of treatment while pregnant, depending on the stage of breast cancer while pregnantthe type of breast cancer, and how far the pregnancy has progressed. 

Is Chemotherapy Safe During Pregnancy?

A key question many people ask is: is chemotherapy safe during pregnancy? 

The answer depends largely on the stage of pregnancy. 

Medical guidelines state that chemotherapy is not recommended during the first trimester, because this is when the baby’s organs are developing. Exposure to chemotherapy drugs during this early stage may increase the risk of miscarriage or birth defects. 

However, research and clinical experience show that most chemotherapy used in the treatment of breast cancer can often be safely given during the second trimester and third trimesters, when the baby’s major organs have already formed. At this stage, the risk of harm to the unborn baby is significantly lower. 

This approach allows doctors to continue treating the cancer without waiting until after delivery. 

Some other breast cancer treatments, such as trastuzumab, endocrine (hormonal) therapy such as tamoxifen and immunotherapy such as pembrolizumab, are not recommended for use at any stage during pregnancy due to risks to the baby. Doctors also carefully check which symptom control medications, like anti-nausea medications, can be safely given during pregnancy. 

For more information about treatment guidelines during breast cancer, visit Cancer Australia. 

What Trimester Can You Have Chemotherapy? 

The timing of chemotherapy during pregnancy is carefully planned. In general: 

Chemotherapy in first trimester (weeks 1–12): 

  • Chemotherapy is not recommended. 
  • This is when the baby’s organs are developing, so exposure to chemotherapy carries the greatest risk. 

Chemotherapy in second trimester (weeks 13–27): 

  • Chemotherapy is commonly given during the second trimester. 
  • The baby’s organs have already formed, reducing the risk of major birth defects. 

Chemotherapy in third trimester (weeks 28–birth): 

  • Chemotherapy may still be given in the third trimester, depending on the situation. 
  • Treatment is usually paused several weeks before delivery so that both mother’s and baby’s blood counts can recover and reduce the risk of complications during birth. 

Every pregnancy and cancer diagnosis is different, so the timing of treatment is tailored to each individual. 

How Does Chemotherapy Affect the Unborn Baby?

When chemotherapy is given during the first trimester, it can interfere with early organ development which may increase the risk of miscarriage or birth defects. This is why it is avoided during this stage of pregnancy. 

When chemotherapy is given after the first trimester, research suggests that most babies are born healthy. However, some risks can still occur, including: 

  • Lower birth weight 
  • A higher chance of early (preterm) delivery 
  • Temporary effects like low blood cell counts related to timing of chemotherapy administration 

Encouragingly, studies following children exposed to chemotherapy in the womb during the second or third trimester generally show normal growth and development. 

To minimise risks, pregnancies are closely monitored by specialists throughout treatment. 

Is Breast Cancer During Pregnancy More Aggressive? 

Breast cancer diagnosed during pregnancy can be more aggressive than breast cancer diagnosed in non-pregnant women. It can also be more advanced at diagnosis because pregnancy-related breast changes can make tumours harder to detect. Whilst the same types of breast cancer affect both pregnant women  and non-pregnant women, there are slightly higher rates of triple negative and HER2 positive breast cancers.  

This is why any unusual breast changes during pregnancy – such as a lump, skin changes, or nipple discharge – should be assessed promptly. 

Early assessment helps ensure that effective treatment can begin as soon as possible. 

What Happens If You Need Chemotherapy While Pregnant?

If chemotherapy is recommended during pregnancy, care is usually managed by a multidisciplinary medical team. This may include: 

  • Medical oncologists 
  • Obstetricians experienced in high-risk pregnancies 
  • Breast surgeons 
  • Specialist nurses and midwives 

Together, they create an individualised treatment plan that carefully balances cancer treatment with pregnancy care. 

This typically includes: 

  • Careful timing of chemotherapy cycles 
  • Regular monitoring of the baby’s growth 
  • Coordination of cancer treatment with the expected delivery date 
  • Emotional and psychological support 

For many women, this coordinated approach allows them to continue their pregnancy while receiving essential cancer treatment. 

Other breast cancer treatments and pregnancy 

There are other treatments that are a part of breast cancer management, including surgery and radiotherapy. 

Surgery for breast cancer, including have an anaesthetic is considered low risk after the first trimester.  

Radiotherapy poses a significant risk to the baby and is delayed until after the baby is delivered. 

Frequently Asked Questions

Can you have chemotherapy while pregnant?

Yes, in many cases chemotherapy can be given during pregnancy, particularly during the second and third trimesters. It is generally avoided in the first trimester due to risks to the developing baby. 

What trimester is chemotherapy safe during pregnancy?

Chemotherapy is usually considered safest during the second and third trimesters, when the baby’s organs have already developed. 

How does chemotherapy affect the unborn baby?

When given after the first trimester, most babies are born healthy. Possible risks include lower birth weight or early delivery, but long-term development is generally normal. 

Is breast cancer during pregnancy more aggressive?

Breast cancer diagnosed during pregnancy can be more aggressive. It can also be detected later because normal pregnancy changes can make tumours harder to detect. However, it is still very treatable with the care of multidisciplinary team. 

Can you breastfeed during chemotherapy?

No. Chemotherapy drugs can pass into breast milk and may harm the baby. Breastfeeding is not recommended while receiving chemotherapy. 

What are the treatment options when pregnant? 

Some treatments – such as endocrine (hormone) therapy, immunotherapy and certain targeted therapies – cannot be used during pregnancy. Chemotherapy may be used in later pregnancy if needed. Treatment plans are always personalised.  

What if you want to become pregnant after breast cancer treatment?

If you are thinking about pregnancy after treatment, watch our recorded Q&A webinar on fertility and breast cancer. Research such as the POSITIVE clinical trial is helping doctors understand how women taking endocrine therapy may safely pause treatment in order to attempt pregnancy under medical supervision. 

Find out more about recent research into interrupting endocrine therapy, to attempt pregnancy after breast cancer. 

Sources:

https://www.cancer.gov/types/breast/breast-cancer-during-pregnancy 

https://www.mdpi.com/1718-7729/31/4/171 

https://www.cancer.nsw.gov.au/about-cancer/document-library/gestational-breast-cancer-in-new-south-wales-a-pop

Join Our Free Q&A Webinars

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Join our FREE Q&A webinars, where we cover important topics including whether more young women are being diagnosed with breast cancer.

Stay Connected with Breast Cancer Trials

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Sign up to our researcher’s newsletter via the form below to stay up to date.

Name(Required)

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

split-banner-image

RACE FOR A CURE DRIVES RECORD FUNDS FOR BREAST CANCER TRIALS

Team Thryv & Race For A Cure has taken out first place in the 2026 Bathurst 6 Hour event, marking a major milestone not only on the track, but for life-saving breast cancer research.

Race For A Cure Drives Record Funds for Breast Cancer Trials

Team Thryv & Race For A Cure has taken out first place in the 2026 Bathurst 6 Hour event, marking a major milestone not only on the track, but for life-saving breast cancer research.

Over Easter weekend at the Bathurst 6 Hour, the Race For A Cure team took out 1st place, capping off an extraordinary campaign that continues to grow year-on-year. Following this year’s event, Race For A Cure has now raised more than $308,000 for Breast Cancer Trials which includes significant contributions from the team’s primary sponsor, Thryv.

Driven by supercar driver Thomas Randle alongside brothers Ben and Michael Kavich, the team’s first-place finish was described as an emotional and deeply meaningful achievement. Their campaign has always been about more than motorsport – it’s about turning personal experience into action.

Race For A Cure was born after the Kavich family’s mother, Toula, was diagnosed with breast cancer following the inaugural Bathurst 6 Hour in 2016. What started as a deeply personal journey has evolved into a powerful national fundraising movement, with more than $266,000 raised prior to this year’s event alone.

“Race For A Cure has always come from the heart,” explains Ben KavichWhat started as something deeply personal for our family has grown into a platform that lets us give back in a meaningful way and keep pushing for better outcomes for others facing breast cancer.”

The team’s impact goes beyond dollars raised. Their story resonates with patients, families and supporters across Australia and shows how communities can drive real change.

The Breast Cancer Trials team would like to extend our sincere thanks to the entire Race For A Cure team – Thomas Randle, Ben and Michael Kavich, their dedicated crew, partners and supporters – for their unwavering commitment to our mission.

Your passion and generosity continue to inspire us and so many others across Australia. By using your platform to raise awareness and vital funds, you are helping to drive forward life-saving research.

With a Bathurst 6 Hour win now added to their legacy, Race For A Cure continues to prove that motorsport can be a force for good. As the total fundraising figure climbs beyond $308,000 and counting, the team remains focused on what matters most: funding research that saves lives.

Learn more about Race For A Cure and donate here.

profile image

Race For A Cure

Race For A Cure is an annual initiative created by Ben, Toula and Michael Kavich. Ben and Michael participate in the Bathurst 6 Hour event held every Easter, raising both awareness and funds for the life-saving research conducted by Breast Cancer Trials.

Support Race For A Cure

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

COULD PATIENTS WITH BREAST CANCER SAFELY SKIP RADIATION? INSIDE THE ROSALIE CLINICAL TRIAL

We sat down with Professor Boon Chua, as she discusses how ROSALIE aims to de-escalate treatment for women with early-stage breast cancer who achieve a complete response to chemotherapy, potentially reducing side effects without compromising outcomes.  

Could Patients with Breast Cancer Safely Skip Radiation & the Potential Side Effects? Inside the ROSALIE Clinical Trial

Could skipping radiation after breast conserving surgery be safe for some patients? The ROSALIE trial is exploring this possibility. We sat down with Professor Boon Chua, Radiation Oncologist and Professor of Medicine at the University of New South Wales, who leads the Breast Cancer Trials ROSALIE clinical trial.  

Professor Chua discusses how the study aims to de-escalate treatment for women with early-stage breast cancer who achieve a complete response to chemotherapy, potentially reducing side effects without compromising outcomes.

“We’ve seen remarkable advances, in the treatment of breast cancer over recent years. Usually, patients who present with early-stage breast cancer would have a range of treatments, including radiotherapy, chemotherapy, hormone therapy, etc.” 

“Increasingly, patients are having systemic therapy upfront, which includes chemotherapy and other forms of targeted therapy to try to downsize their cancer and to make them smaller, so that patients who otherwise would need a mastectomy (the removal of the whole breast) would then have the option of having breast conserving surgery. This means having only the cancer itself exercised.”

“And usually this would be followed by trying to eradicate any residual cancer cells. With the increasing effectiveness of chemotherapy and other forms of systemic therapy, they find that, more women who have chemotherapy and systemic therapy upfront, are found to have no residual cancer cells at a time of their breast conserving surgery.” 

Listen to the podcast

Could skipping radiation after breast conserving surgery be safe for some patients? The ROSALIE trial is exploring this possibility. We sat down with Professor Boon Chua, Radiation Oncologist and Professor of Medicine at the University of New South Wales, who leads the Breast Cancer Trials ROSALIE clinical trial.  

key take away icon

Key takeaways

  • Better chemotherapy is changing what comes next
    Advances in chemotherapy and targeted therapies mean many women with early-stage breast cancer now achieve a complete response before surgery—no detectable cancer cells at the time of breast-conserving surgery. This progress opens the door to rethinking whether all traditional follow-up treatments are still necessary.
  • The ROSALIE trial asks a big, patient-centred question
    The core question of the ROSALIE clinical trial is whether radiotherapy can be safely omitted for women who have no residual cancer after upfront systemic therapy and breast-conserving surgery. It’s about testing safety without compromising cancer outcomes.

  • Skipping radiation could reduce side effects and costs—if proven safe
    If outcomes are equivalent for patients who skip radiation, this could spare women from the physical side effects, emotional burden, and financial costs of radiotherapy, while still maintaining excellent cancer control.

  • This is a move toward truly personalised breast cancer care
    ROSALIE represents a broader shift toward treatment de-escalation and personalisation—tailoring care based on how an individual patient’s cancer responds to therapy, rather than applying the same treatment pathway to everyone. Clinical trial participation is key to building the evidence that makes this possible.

Can you tell us about the ROSALIE clinical trial and what the study is hoping to find out?

“So, all of this raises the question of whether these patients should routinely receive radiotherapy, which aims to eradicate any residual cancer cells. And therefore, through Breast Cancer Trials, we’re launching a new study called the ROSALIE Study.”

“And ROSALIE aims to test whether it is safe to omit radiation after breast conserving surgery in women who have received upfront chemotherapy and other systemic therapy and are found to have no residual cancer cells in the breast tissue at the time of surgery.” 

How could this research change the way we treat breast cancer in the future, especially for patients with early-disease?

If the study shows that women who omit radiation, have outcomes that are no worse than those patients who would routinely have radiotherapy then these patients will be able to avoid radiotherapy and the side effects and the financial cost of this treatment. 

“This would then support the clinicians and patients to personalise or tailor the use of radiotherapy according to their individual responses to chemotherapy and assisted therapy.”

What would you like patients and the public to understand about the importance of participating in a trial like this?

“The study may be suitable for you if you have early-stage breast cancer that hasn’t spread to the lymph nodes. There is no greater privilege than having the opportunity to work with our patients and supporting them to achieve the best outcomes possible.” 

“For them as individuals there are usually options for every patient who presents with breast cancer. So, what we try to do in conducting research such as the ROSALIE study, is to generate the evidence that would then allow us to tailor the treatment, as in the need for radiotherapy or other forms of treatment, according to the individual needs of the patient.” 

“Clinical trials are often costly to conduct, especially for studies like ROSALIE that depend heavily on public support and public funding for its successful conduct. And therefore, we are very grateful for your support in allowing us at Breast Cancer Trials to conduct research that ultimately would benefit our patients and our future generations – so thank you.” 

QUICK ACCESS

profile image

Professor Boon Chua

Professor Boon Chua is a Radiation Oncologist and Professor of Medicine at the University of New South Wales, and is the Study Chair of the Breast Cancer Trials ROSALIE clinical trial.

Support Breast Cancer Research

Could Patients with Breast Cancer Safely Skip Radiation? Inside the ROSALIE Trial

We sat down with Professor Boon Chua, as she discusses how ROSALIE aims to de-escalate treatment for women with early-stage breast cancer who achieve a complete response to chemotherapy, potentially reducing side effects without compromising outcomes. 

Podcast Transcript

  •  Could Patients With Breast Cancer Safely Skip Radiation & the Potential Side Effects? Inside the ROSALIE Clinical Trial 

    Could skipping radiation after breast conserving surgery be safe for some patients? The ROSALIE trial is exploring this possibility. In this episode, we sit down with Professor Boon Chua, Radiation Oncologist and Professor of Medicine at the University of New South Wales, who leads the Breast Cancer Trials ROSALIE clinical trial.  

    Professor Chua discusses how the study aims to de-escalate treatment for women with early-stage breast cancer who achieve a complete response to chemotherapy, potentially reducing side effects without compromising outcomes.  

    “We’ve seen remarkable advances, in the treatment of breast cancer over recent years. Usually, patients who present with early-stage breast cancer would have a range of treatments, including radiotherapy, chemotherapy, hormone therapy, etc.” 

    “Increasingly, patients are having systemic therapy upfront, which includes chemotherapy and other forms of targeted therapy to try to downsize their cancer and to make them smaller, so that patients who otherwise would need a mastectomy (the removal of the whole breast) would then have the option of having breast conserving surgery. This means having only the cancer itself exercised.” 

    “And usually this would be followed by trying to eradicate any residual cancer cells. With the increasing effectiveness of chemotherapy and other forms of systemic therapy, they find that, more women who have chemotherapy and systemic therapy upfront, are found to have no residual cancer cells at a time of their breast conserving surgery.” 

    Can you tell us about the ROSALIE clinical trial and what this study is hoping to find out?  

    “So, all of this raises the question of whether these patients should routinely receive radiotherapy, which aims to eradicate any residual cancer cells. And therefore, through Breast Cancer Trials, we’re launching a new study called the ROSALIE Study.” 

    “And ROSALIE aims to test whether it is safe to omit radiation after breast conserving surgery in women who have received upfront chemotherapy and other systemic therapy and are found to have no residual cancer cells in the breast tissue at the time of surgery.” 

    How could this research change the way we treat breast cancer in the future, especially for patients with early-stage disease? 

    “If the study shows that women who omit radiation, have outcomes that are no worse than those patients who would routinely have radiotherapy then these patients will be able to avoid radiotherapy and the side effects and the financial cost of this treatment.” 

    “This would then support the clinicians and patients to personalise or tailor the use of radiotherapy according to their individual responses to chemotherapy and assisted therapy.” 

    What would you like patients and the public to understand about the importance of participating in trials like this and who is eligible to participate in ROSALIE?  

    “The study may be suitable for you if you have early-stage breast cancer that hasn’t spread to the lymph nodes. There is no greater privilege than having the opportunity to work with our patients and supporting them to achieve the best outcomes possible.” 

    “For them as individuals there are usually options for every patient who presents with breast cancer. So, what we try to do in conducting research such as the ROSALIE study, is to generate the evidence that would then allow us to tailor the treatment, as in the need for radiotherapy or other forms of treatment, according to the individual needs of the patient.” 

    “Clinical trials are often costly to conduct, especially for studies like ROSALIE that depend heavily on public support and public funding for its successful conduct. And therefore, we are very grateful for your support in allowing us at Breast Cancer Trials to conduct research that ultimately would benefit our patients and our future generations – so thank you.” 

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

split-banner-image

TP53 MUTATION AND BREAST CANCER

The TP53 genetic mutation can increase the risk of breast cancer. Learn more about this particular gene and how genetics are influencing research. 

DNA building blocks are responsible for making genes, the blueprint of instructions for the human body and its functioning components. One specific gene called TP53, plays a crucial role in protecting our DNA and preventing breast cancer development. When changes (mutations) occur in this gene, they can significantly increase the risk of certain cancers, including breast cancer. 

Understanding the role of the TP53 gene and what it means if you carry a TP53 mutation, can help individuals and families make informed decisions about their health, screening, and treatment options. 

What is the TP53 gene? 

The TP53 gene provides instructions for making a protein called p53, often referred to as the “guardian of the genome.” This protein helps regulate the repair of damaged DNA, controls how quickly cells divide, and triggers the natural death of cells when something goes wrong. 

When the TP53 gene is working normally, it helps protect the body from cancer. But if it is altered or damaged, cells can grow uncontrollably, leading to tumour formation. 

Everyone has two copies of the TP53 gene – one inherited from each biological parent. These genes produce a protein that helps protect the body by repairing DNA damage or removing cells that aren’t functioning properly. Because TP53 acts as a tumour-suppressor gene, it plays an important role in preventing breast cells from turning cancerous. 

How common is a TP53 mutation? 

TP53 mutations are relatively rare compared to other genetic mutations like BRCA1 and BRCA2. However, when they are present, they are strongly linked to a higher risk of several types of cancer, particularly early-onset breast cancer. 

According to Cancer Australia, women with a TP53 mutation have around five times the risk of developing breast cancer compared to women without the mutation. This increased risk is particularly pronounced in women under the age of 40, where breast cancer occurs more frequently and often at younger ages. 

TP53 and breast cancer risk 

A TP53 mutation increases the risk of several cancers including breast, brain, bone, soft tissue, and adrenal cancers. For women, breast cancer is one of the more common cancers associated with this mutation, and typically occurs earlier in life than in the general population. 

In many cases, TP53 mutations occur as part of a hereditary condition known as Li-Fraumeni Syndrome (LFS). People with this inherited condition have a significantly increased lifetime risk of developing multiple cancers, often before the age of 40.  

Although TP53 mutations can influence how a tumour behaves, many factors affect outcomes, including early detection and access to appropriate treatment.  

Research suggests that breast cancers associated with a TP53 mutation, on average, have lower recurrence-free and overall survival compared with breast cancers without this mutation. However, TP53 status is only one of many factors that can influence breast cancer outcomes. Individual prognosis can vary widely depending on the type of breast cancer, the stage at diagnosis, and the treatments received. For this reason, TP53 mutation status is considered alongside other clinical factors when planning care and follow-up.  

Overall, a TP53 mutation can influence prognosis, but it is only one part of the bigger picture. Factors such as early detection and personalised treatment also play a major role. 

TP53 gene testing 

Genetic testing for TP53 may be recommended for people who have: 

  • breast cancer diagnosed before age 31 
  • a strong family history of some early-onset cancers, such as breast cancer, brain tumours, soft tissue or bone sarcomas, or adrenal cortical cancer 
  • multiple different cancers in one individual 
  • features that suggest an inherited cancer condition 
  • Rare cancers that are associated with a defective p53 gene  

Testing is typically done through a blood or saliva sample.  Because the results can have important medical and emotional implications, genetic counselling is an essential part of the process. Counselling helps explain what the results may mean for you and your family and guides decisions about screening and management

Living with a TP53 mutation 

If you carry a TP53 mutation, your healthcare team may recommend a personalised approach to monitoring and reducing breast cancer risk. This may include the following strategies: 

  • Enhanced breast screening, such as regular breast MRI from age 20 
  • Risk-reducing surgical options, which may be discussed depending on your personal and family history 
  • Risk-reducing medications, such as estrogen blocking tablets may be considered to reduce the risk of hormone positive breast cancer occurrence  
  • Lifestyle considerations, such as maintaining a healthy weight, limiting alcohol, staying physically active, avoiding excessive sun exposure and avoiding tobacco 
  • Psychosocial support, including counselling services to help navigate decisions and family communication. 

Whilst the above advice is specific to breast cancer. Guidelines also suggest colonoscopy and gastroscopy for colon cancer and gastric cancers, whole body MRI for sarcoma, annual skin checks for melanoma, and annual brain MRI for brain cancer. 

These steps aim to support early detection and provide clearer pathways for managing breast cancer risk. 

Latest research and clinical trials 

Australian guidelines recognise TP53 as an important hereditary breast cancer gene, and there is ongoing work to better understand how reduced TP53 function influences cancer risk and early tumour development. National resources such as Cancer Australia and eviQ provide guidance on screening, risk reduction and support for people with inherited TP53 mutations, including those with Li-Fraumeni syndrome. 

While there has been some hype surrounding pre-clinical models targeting mutant p53, clinical trials have failed to show success in drugs that target p53 to date. There are ongoing clinical trials focusing on targeting mutant p53 protein and reactivating its normal form. 

The importance of TP53 awareness and action 

If you have a family history of early-onset or multiple cancers, speaking with your general practitioner or a genetic counsellor can help determine whether TP53 testing is appropriate. Understanding your genetic risk supports informed decision-making and can guide screening, treatment and prevention options tailored to your needs. 

Resources, clinical trials and support services can help you and your family navigate the next steps. 

Frequently Asked Questions

What does a TP53 mutation lead to?

A TP53 mutation can reduce the body’s ability to manage DNA damage. This increases the chance that abnormal cells will grow and potentially develop into cancer. The specific risks vary depending on the individual and whether the mutation is inherited.

What does TP53 positive mean?

A “TP53 positive” result means that a genetic test has identified a harmful change in the TP53 gene. It does not mean you have cancer, but it does mean your cancer risk is increased compared to the general population. Your general practitioner or genetics counsellor will recommend a tailored screening and management plan.

What is a faulty TP53 Gene?

A “faulty” TP53 gene is one that has a harmful change, or mutation, which stops it from working as it should. Normally, TP53 helps protect the body by repairing DNA damage or removing cells that aren’t functioning properly. If one of the two TP53 genes you inherit from your biological parents is faulty, this protective process is weakened. This can increase the chance of abnormal breast cells developing into cancer over time.

Join Our Free Q&A Webinars

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Join our FREE Q&A webinars, where we cover important topics including whether more young women are being diagnosed with breast cancer.

Stay Connected with Breast Cancer Trials

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Sign up to our researcher’s newsletter via the form below to stay up to date.

Name(Required)

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

split-banner-image

WHAT I WISH I KNEW BEFORE MY MASTECTOMY

Merryn shares her breast cancer journey, from mastectomy to reconstruction and life beyond treatment.

Being told you need a mastectomy as part of your breast cancer treatment is very confronting. At the time I thought “OK, I want to live, I can live without my right breast”. But I underestimated the impact it would later have on the use of my right arm and shoulder, and my self-confidence.

Once I’d completed all my chemo and radiotherapy treatment, I decided to swim laps. I gradually increased to swimming 1km two or three times a week. This helped me feel strong again. I loved the water but wearing a prosthetic right breast in my swimmers was awkward and made me feel uncomfortably self-conscious.

After two years, I had a breast reconstruction. This was the best decision. Not only did the reconstruction make me feel physically whole again, it also improved my self-confidence and emotional wellbeing. I had completely underestimated how much a reconstruction would help me heal mentally and emotionally. So, with the benefit of hindsight, I would have planned my reconstruction as early as practical.

Ten years of lap swimming later, I developed rotator cuff issues in my right shoulder, which can’t be surgically fixed due to lymphoedema in my right arm. Perhaps I overdid the swimming. It would have been better to be guided by a physiotherapist with experience of mastectomy recovery. (Be proactive about seeking advice!)

Survival rates from breast cancer are increasing – the vast majority of people now go on to live long lives. It’s so important to seek specialist professional support for your rehabilitation after mastectomy, to minimise the long term side effects.

So, with the benefit of hindsight, I would have planned my reconstruction as early as practical. (Do it at the time of your mastectomy if your medical team advises that’s OK.) And I would have sought specialist physiotherapist support for my rehabilitation.

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

split-banner-image

2025 SAN ANTONIO BREAST CANCER SYMPOSIUM

A summary of key announcements and research developments presented at the 2025 San Antonio Breast Cancer Symposium (SABCS).

2025 San Antonio Breast Cancer Symposium

The 2025 San Antonio Breast Cancer Symposium (SABCS) brought together researchers, clinicians, and consumers from around the world to share the latest advances in breast cancer research and care.

This year’s meeting highlighted important progress across the full spectrum of breast cancer – from earlier diagnosis and less invasive surgery, to more effective and better-tolerated treatments for both early and advanced disease. Several studies focused on personalising care, reducing unnecessary treatment, and improving quality of life, while others explored new therapies that can help people live longer with fewer side effects.

Below is a summary of research highlights from SABCS 2025.

Neo-N

The Neo-N clinical trial is an Australian study, that was coordinated by Breast Cancer Trials, and examined whether adding newer immunotherapy treatments to shorter duration chemotherapy before surgery, can safely and effectively treat early-stage triple negative breast cancer—an aggressive form of the disease.

This study found that a series of blood tests to detect ‘circulating tumour DNA’, could help inform the future of triple negative breast cancer treatment.

The tests look for tiny fragments of tumour DNA that have been released by the breast cancer into the blood. Researchers found that when this tumour DNA could not be detected during or after treatment, women were more likely to have no remaining signs of cancer at the time of surgery and had better long-term survival outcomes.

Currently, patients with early stage triple negative breast cancer often need long duration multi-agent chemoimmunotherapy, which can cause significant side effects. This study is exploring whether some of that chemotherapy can be safely replaced with immunotherapy while still achieving strong results for patients.

Study Chair Professor Sherene Loi explained that these results could mean a new horizon for triple negative breast cancer, which accounts for approximately 15% of all breast cancers diagnosed.

“Clearance of circulating tumour DNA indicates that the treatment on the tumour appears to be working and killing off the cancer,” explained Professor Loi. “Triple negative is a type of breast cancer that is lacking features we can target, unlike other breast cancer types, making it a difficult breast cancer to treat, so these latest results are an exciting breakthrough.”

The Neo-N trial recruited patients at 18 institutions in Australia and New Zealand, and an institution in Italy, with a total of 108 participants with triple negative breast cancer. The Study Chair was Professor Sherene Loi.

Click here for more information about Neo-N clinical trial results.

HER2CLIMB-05

This study focused on people with HER2-positive metastatic breast cancer receiving their first treatment. All participants had already completed initial chemotherapy and HER2-targeted treatment and their cancer had not worsened. Many had cancer that had spread to organs such as the liver or lungs, and about half also had hormone receptor–positive disease.

The study tested whether adding a drug called tucatinib to ongoing HER2-targeted treatment could delay cancer growth. The results were encouraging: people who received tucatinib lived almost nine months longer on average before their cancer progressed compared with standard treatment alone.

The benefit was seen across all groups, regardless of hormone receptor status. So far, there has been no clear evidence that tucatinib reduced the risk of cancer spreading to the brain compared with standard treatment, although follow-up is ongoing.

Side effects were generally manageable. While diarrhoea was common in both treatment groups, only a small number of people stopped treatment because of it, suggesting the drug is well tolerated.

Recent studies have also shown strong results from other treatment approaches in this setting, including combining hormone therapy with targeted drugs or using newer antibody-drug therapies. As a result, doctors and patients now have several effective options potentially available, however deciding which is best will remain a challenge until more data become available.

LidERA

LidERA is the first major study to show that a newer type of hormone therapy can work better than standard treatment, in people with early hormone receptor–positive breast cancer.

The drug tested, giredestrant, is a next-generation oral therapy that blocks and breaks down the oestrogen receptor, helping to stop cancer cells from growing. The study included people with a range of cancer stages, from lower to higher risk of recurrence.

After nearly three years of follow-up, giredestrant reduced the risk of cancer returning by a small but meaningful amount compared with standard hormone therapy. This improvement was seen consistently across different patient groups, including those with higher-risk disease. Importantly, more than 9 out of 10 people taking giredestrant were cancer-free three years after treatment.

Side effects were similar to standard therapy, but fewer people stopped the new treatment because of side effects, suggesting giredestrant may be easier to stay on long-term.

Better-tolerated hormone treatments are important because they can help people stay on therapy and reduce the chance of cancer returning. Questions remain about whether combining giredestrant with other targeted drugs would provide even greater benefit, and how affordable widespread use would be.

AXSANA

Surgery to remove lymph nodes from the armpit has traditionally been used to help stage breast cancer and reduce the risk of spread. However, less extensive surgery may be just as safe for many patients.

AXSANA studied people whose cancer initially involved lymph nodes but appeared to clear after chemotherapy given before surgery. The goal was to see whether less aggressive lymph node surgery could safely replace full removal of lymph nodes.

After three years of study follow-up, the risk of cancer returning in the armpit was extremely low (99%), regardless of how much surgery was performed. Most patients also received radiation to the lymph node area, which likely contributed to these excellent results.

People who had more extensive surgery tended to have more aggressive disease overall, explaining higher rates of cancer spread elsewhere in the body—but not higher lymph node recurrence.

Longer follow-up is still needed, but this study supports the growing move toward less invasive surgery when it is safe to do so.

BOOG 2013-08

This Dutch study looked at whether sentinel lymph node biopsy—a common surgical procedure—can be safely omitted in selected people with small, early-stage breast cancer and no signs of lymph node involvement.

Most participants in this study were older than 50 and had slow-growing, hormone-positive cancers. After five years, people who did not have the procedure had outcomes that were just as good as those who did, in terms of cancer returning in nearby lymph nodes. Earlier results had already shown that avoiding this surgery led to better quality of life.

These results support a less-is-more approach for carefully selected patients, although doctors may be cautious about applying this to younger people until more long-term data are available.

TROG 07.01

This Australian-led study examined whether giving extra radiation to the tumour site after standard breast radiation reduces the risk of cancer returning in people with ductal carcinoma in situ (DCIS) that is not considered to be at low risk of recurrence.

After 10 years, people who received the extra “boost” radiation had a lower chance of cancer returning, including fewer invasive cancers. This benefit was seen regardless of the radiation schedule used.

Overall survival was the same for both groups. The boost did lead to more side effects such as skin irritation and breast discomfort, but these were usually mild.

This is the first long-term randomised study showing that boost radiation benefits people under 50, or older people with higher-risk DCIS features.

Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2

People with BRCA1 or BRCA2 gene mutations face high risks of breast and ovarian cancer. Surgery to remove the ovaries reduces ovarian cancer risk but causes early menopause, which can have serious short- and long-term health effects.

This study looked at whether menopausal hormone therapy (MHT) is safe for these women without a past history of breast cancer, after either menopause or preventive surgery to remove their ovaries. Reassuringly, women who used oestrogen therapy did not have higher breast cancer rates—in fact, rates were lower compared with those who did not use hormones.

No increased risk was seen with combined oestrogen-progesterone therapy either. These findings support the safe use of MHT in women with BRCA mutations who are experiencing significant menopausal symptoms, helping improve quality of life, bone and cardiovascular health.

WISDOM

The WISDOM trial studied a new approach to breast cancer screening based on individual risk, rather than the same schedule for everyone.

Participants had their risk assessed using personal factors, breast density, and genetic testing. Screening frequency and age of commencement were then tailored accordingly.

This approach was at least as effective as annual screening and may even be better, with fewer advanced cancers diagnosed, fewer mammograms performed, and lower overall costs. Genetic testing through mailed saliva kits was widely accepted, identifying people at higher risk who would not have been identified based on family history alone. Analysis of cost were also favourable compared with standard screening.

While risk-based screening requires more effort from participants, it offers a promising and more personalised way to screen for breast cancer.

PREFER

PREFER focused on fertility preservation in younger people diagnosed with breast cancer who needed chemotherapy.

The study showed that ovarian stimulation and egg freezing did not increase the risk of cancer returning or affect survival. In fact, outcomes were slightly better in those who preserved fertility, especially in hormone-positive cancers, although this difference was not statistically definitive.

Most participants also received treatment to protect ovarian function during chemotherapy. These results provide strong reassurance that fertility preservation is safe and should be routinely offered to eligible patients.

EMBER-3

EMBER-3 studied treatments for people with advanced hormone-positive breast cancer, whose disease had developed resistance to standard hormone therapy.

A newer hormone therapy, imlunestrant, worked better than standard options at delaying cancer progression, particularly when combined with the targeted drug abemaciclib.

Overall survival results showed a trend toward benefit but did not meet strict statistical thresholds, requiring longer follow-up to make a definitive conclusion about survival. The findings highlight how treatment choices in this setting are becoming increasingly complex, with several effective options and no clear single best approach yet.

PATINA

The PATINA study focused on people with ER-positive, HER2-positive metastatic breast cancer whose disease had not worsened after initial treatment.

PATINA is an international clinical trial, which enrolled 496 patients worldwide, including 49 patients from Australia and New Zealand through Breast Cancer Trials. The Australian Study Chair of PATINA is Professor Elgene Lim.

Adding the drug palbociclib to ongoing HER2-targeted and hormone therapy significantly delayed cancer progression. This follow-up analysis showed that palbociclib also reduced the risk of cancer spreading to the brain.

Brain metastases can seriously affect quality and length of life. Preventing them is a major goal, even though modern treatments can control disease after it develops. These findings reinforce the value of palbociclib in this treatment setting.

BUY THE DIARY THAT
SAVES LIVES

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

NEXT GEN ONCOLOGY: INSIGHTS FOR TRAINEES AND EARLY-CAREER CLINICIANS

Are you a trainee or early career professional in oncology looking to connect, learn and grow? In this article, we highlight the Trainee and Early Career Day at Breast Cancer Trials Annual Scientific Meeting.

Next Gen Oncology: Insights for Trainees and Early-Career Clinicians

Are you a trainee or early career professional in oncology looking to connect, learn and grow?

In this article, we highlight the Trainee and Early Career Day at Breast Cancer Trials Annual Scientific Meeting. A unique opportunity to network with peers, gain insights from leading researchers and kick start your professional development in the field of breast Cancer Research.

“My name is Michelle Li. I’m an early-career medical oncologist and I’m also a clinician researcher. I work at the Peter MacCallum Cancer Centre and I’m also currently undertaking my PhD which ties in very well to my Breast Cancer Trials (BCT) Clinical Fellowship, which is looking at mechanisms of resistance to T-DXd which is one of our breast cancer drugs.”

My name is Adam Ofri. I’m a breast surgeon, located in Sydney, and I’m also affiliated with BCT.”

“The BCT Trainee and Early Career Day (T&ECD) training and early career day is actually a really important part of the conference. So not only for trainees from medical oncology, which is my specialty, but also from other disciplines including radiation oncology and surgery,” said Michelle.

“It’s really quiet a multidisciplinary environment in which we can get together, they can network, and we can also understand a little bit about other specialties, which really directly impacts upon and influences at work in looking after patients. We get to meet new people, we learn about other specialties, we also get to hear from leaders in the so there’s international speakers from the main conference and also local speakers as well.”

“The day was developed as a means to really engage the younger people, to get the registrars, the fellows and the early career specialists to come to BCT, to get more involved, to get more exposure and more understanding and to be more inclusive,” said Adam.

“The ASM is phenomenal with some really big-name speakers. It’s jam packed with really impressive lectures, but the T&ECD gives the time for those trainees to mingle and interact with these international speakers, have a smaller forum where they can chat and feel more comfortable.”

And the other thing is breast cancer management is so diverse with so many different streams that when you’re a trainee and a fellow, you sort of only stay in your stream. And the trainee day really gives an opportunity for them to start interacting with people in the other streams. Because we all come together at the MDT and gives them an opportunity to actually ask questions as well and understand a little bit of the complexity of the multi-facets of breast cancer management.”

And it’s just fun. It’s an opportunity to chat with people and not be too intimidated to speak to a professor who’s come in from overseas and pick their brains about something,” he said.

Listen to the podcast

Are you a trainee or early career professional in oncology looking to connect, learn and grow? In this episode, we highlight the Trainee and Early Career Day at Breast Cancer Trials Annual Scientific Meeting. A unique opportunity to network with peers, gain insights from leading researchers and kick start your professional development in the field of breast Cancer Research.

key take away icon

Key takeaways

1. A vital platform for connection, learning, and belonging

The Trainee and Early Career Day (T&ECD) offers a rare opportunity for emerging oncologists, surgeons, and allied professionals to connect across disciplines, learn from international leaders, and feel part of the wider Breast Cancer Trials (BCT) community. It helps participants build lasting professional networks and a sense of belonging in the field.


2. A supportive, multidisciplinary learning environment

Unlike the larger Annual Scientific Meeting (ASM), the trainee day provides a more relaxed and interactive setting where participants can freely ask questions, discuss complex cases, and learn from experts in other specialties—helping them understand the full, multidisciplinary scope of breast cancer care.


3. A launchpad for professional growth and research opportunities

Engagement in the T&ECD can lead to meaningful career progression. Michelle Li’s journey—from attending her first trainee day to joining the organising committee and becoming a BCT Clinical Fellow—illustrates how participation can open doors to research collaborations, mentorship, and international experience.


4. Investing in the next generation drives innovation in breast cancer care

Bringing fresh perspectives, new ideas, and enthusiasm from trainees is essential for the continued evolution of breast cancer research and clinical practice. Early-career involvement ensures that future leaders sustain and expand on the progress made through clinical trials—pushing boundaries toward better outcomes for patients.

What can attendees expect from the day?

“For a trainee, when they turn up for the day, we have some lectures, we have opportunities to ask questions galore, it’s encouraged. And then we have typically a stage where we’ve got complex cases that are presented that are selected by fellows who have applied. After that we have the international guest speakers that are attending and they are actually part of the panel that can answer the questions,” said Adam.

“And we get a wide range of input from different subspecialties. And the trainees are just empowered really to fire off questions and to ask the things that they may feel exceptionally intimidated to ask at the ASM. And they can ask world leaders questions to really help their understanding.”

It is a really interesting day. You’re not seeing the same studies that you’ve seen many, many times already. You’re hearing about interesting cases that you might discuss in your day-to-day clinical work. You’re hearing about interesting aspects of your clinical practise you haven’t heard about before,” said Michelle.

“From memory, we’ve talked about treatment in pregnancy, for example, fear of recurrence, dietary recommendations for our patients, it’s really just an opportunity to learn about things that you might not have had an opportunity to learn about before. And at the end of the day, you get to go and bring all the information back to your parent hospitals. There’s also a really good dinner the night before as well where you get to sit down and meet everyone,” she said.

How does the day help people who are just starting out in breast cancer research, or clinical practice?

I find that particularly in a field like breast cancer, you always see the same faces over and over again. And it’s really important to get to know your colleagues so that you can have research collaborations in the future. You can work together in the management of your patients locally and also, you know, within the state. And I think that not only having those connections is really helpful, but I think it also helps you feel like you’re really part of the community and you have a real sense of belonging,” said Michelle.

So, I attended my first trainee day in 2024 when it was up in Cairns. From there, I was invited to be a part of the organising committee. From there I also heard about the BCT Clinical Fellowships, which I’m now a recipient of. And that’s allowed me to go and do further research, particularly internationally with some of our partner hospitals.”

“So really, that first introduction to BCT has really already started me on a much better trajectory for my career than I would have expected. So I think it’s truly very integral to my journey so far,” she said.

“The Trainee and Early Career Day is absolutely relevant to your career. It is a really great experience if you’re already here for the conference or if you’re coming after the conference. I think if you’re interested in breast cancer and you’re interested in meeting other people in the field; this is an absolute no brainer. You should definitely come,” said Michelle.

What would you say to someone who is unsure about attending?

If you’ve got any interest in breast cancer, come along. There’s really nothing to lose, there’s only something to gain. For registrars who are in medical oncology, this is your opportunity to understand what it is that surgeons do or pick the brains of a radiation oncologist. For surgeons, we can actually understand what it is that radiation oncology does and understand a bit more about the drugs of what is being described,” said Adam.

We can also learn more about psychiatry, radiology, understand patient impact, and it just gives an opportunity to wet your palate, if you will, about breast cancer management. And it’s always had a really good outcome,” he said.

Why is it so important that the next generation of researchers and clinicians get involved with Breast Cancer Trials?

As I explained to all of my patients, all the gold standard treatments that they have today were once trials. So, BCT are really the way forward for making sure that we can offer the best treatments to our patients, and we can offer the best outcomes for our patients. And as they have in their main motto, we want to make sure that there are no more lives that are cut short,” said Michelle.

I think breast cancer clinical trials are really where we should be investing our time and our energy, and being a part of the trainee day is just one step forward on that journey. We need to have fresh minds, new thoughts, that’s we need to get change. Breast cancer management has changed so much in the last decade alone, let alone the last 60-80 years,” said Adam.

“And it’s always been because of people thinking outside the box. And you can’t get that by the same group of people. If you don’t want stagnancy, you need to have fresh enthusiasm, new motivation, new ideas, and different ways of thinking.”

“And all of this is really what leads to the dynamic aspect of breast cancer management. It’s what is really promoted and encouraged breast cancer clinical trials research. And we can see some absolutely incredible trials that are coming out that just really take a different mindset, a different way of thinking.”

It’s the only way that you get that, by bringing in new people, young people, and eventually everyone retires, so we need new people to come in to take the reins and improve upon what has already been done really well. I mean, the trainees, the fellows, the early career people are the future of BCT, and it’s all about making everyone feel as included and as comfortable as possible,” he said.

QUICK ACCESS

profile image

Dr Michelle Li

Dr Michelle Li is a Medical Oncologist & Advanced Research Fellow at Dana-Farber Cancer Institute.
profile image

Dr Adam Ofri

Adam Ofri is a Breast Surgeon with Northern Breast Care at the Mater Hospital, Sydney. He has a strong interest in patient-tailored breast cancer management and has a passion for academia.

Support Breast Cancer Research

Next Gen Oncology: Insights for Trainees and Early-Career Clinicians

Are you a trainee or early career professional in oncology looking to connect, learn and grow? In this episode, we highlight the Trainee and Early Career Day at Breast Cancer Trials Annual Scientific Meeting.

Podcast Transcript

  • Next Gen Oncology: Insights for Trainees and Early-Career Clinicians

    Are you a trainee or early career professional in oncology looking to connect, learn and grow? In this episode, we highlight the Trainee and Early Career Day at Breast Cancer Trials Annual Scientific Meeting. A unique opportunity to network with peers, gain insights from leading researchers and kick start your professional development in the field of breast Cancer Research.

    “My name is Michelle Li. I’m an early-career medical oncologist and I’m also a clinician researcher. I work at the Peter MacCallum Cancer Centre and I’m also currently undertaking my PhD which ties in very well to my Breast Cancer Trials (BCT) Clinical Fellowship, which is looking at mechanisms of resistance to T-DXd which is one of our breast cancer drugs.”

    My name is Adam Ofri. I’m a breast surgeon, located in Sydney, and I’m also affiliated with BCT.”

    “The BCT Trainee and Early Career Day (T&ECD) training and early career day is actually a really important part of the conference. So not only for trainees from medical oncology, which is my specialty, but also from other disciplines including radiation oncology and surgery,” said Michelle.

    “It’s really quiet a multidisciplinary environment in which we can get together, they can network, and we can also understand a little bit about other specialties, which really directly impacts upon and influences at work in looking after patients. We get to meet new people, we learn about other specialties, we also get to hear from leaders in the so there’s international speakers from the main conference and also local speakers as well.”

    “The day was developed as a means to really engage the younger people, to get the registrars, the fellows and the early career specialists to come to BCT, to get more involved, to get more exposure and more understanding and to be more inclusive,” said Adam.

    “The ASM is phenomenal with some really big-name speakers. It’s jam packed with really impressive lectures, but the T&ECD gives the time for those trainees to mingle and interact with these international speakers, have a smaller forum where they can chat and feel more comfortable.”

    And the other thing is breast cancer management is so diverse with so many different streams that when you’re a trainee and a fellow, you sort of only stay in your stream. And the trainee day really gives an opportunity for them to start interacting with people in the other streams. Because we all come together at the MDT and gives them an opportunity to actually ask questions as well and understand a little bit of the complexity of the multi-facets of breast cancer management.”

    And it’s just fun. It’s an opportunity to chat with people and not be too intimidated to speak to a professor who’s come in from overseas and pick their brains about something,” he said.

    If someone’s never attended before, what can they expect from the day?

    “For a trainee, when they turn up for the day, we have some lectures, we have opportunities to ask questions galore, it’s encouraged. And then we have typically a stage where we’ve got complex cases that are presented that are selected by fellows who have applied. After that we have the international guest speakers that are attending and they are actually part of the panel that can answer the questions,” said Adam.

    “And we get a wide range of input from different subspecialties. And the trainees are just empowered really to fire off questions and to ask the things that they may feel exceptionally intimidated to ask at the ASM. And they can ask world leaders questions to really help their understanding.”

    It is a really interesting day. You’re not seeing the same studies that you’ve seen many, many times already. You’re hearing about interesting cases that you might discuss in your day-to-day clinical work. You’re hearing about interesting aspects of your clinical practise you haven’t heard about before,” said Michelle.

    “From memory, we’ve talked about treatment in pregnancy, for example, fear of recurrence, dietary recommendations for our patients, it’s really just an opportunity to learn about things that you might not have had an opportunity to learn about before. And at the end of the day, you get to go and bring all the information back to your parent hospitals. There’s also a really good dinner the night before as well where you get to sit down and meet everyone,” she said.

    So how does the day help people who are just starting out in breast cancer research or clinical practise?

    I find that particularly in a field like breast cancer, you always see the same faces over and over again. And it’s really important to get to know your colleagues so that you can have research collaborations in the future. You can work together in the management of your patients locally and also, you know, within the state. And I think that not only having those connections is really helpful, but I think it also helps you feel like you’re really part of the community and you have a real sense of belonging,” said Michelle.

    So, I attended my first trainee day in 2024 when it was up in Cairns. From there, I was invited to be a part of the organising committee. From there I also heard about the BCT Clinical Fellowships, which I’m now a recipient of. And that’s allowed me to go and do further research, particularly internationally with some of our partner hospitals.”

     

    “So really, that first introduction to BCT has really already started me on a much better trajectory for my career than I would have expected. So I think it’s truly very integral to my journey so far,” she said.

    What would you say to someone who’s unsure about coming or thinks it might not be relevant to them?

    If you’ve got any interest in breast cancer, come along. There’s really nothing to lose, there’s only something to gain. For registrars who are in medical oncology, this is your opportunity to understand what it is that surgeons do or pick the brains of a radiation oncologist. For surgeons, we can actually understand what it is that radiation oncology does and understand a bit more about the drugs of what is being described,” said Adam.

    We can also learn more about psychiatry, radiology, understand patient impact, and it just gives an opportunity to wet your palate, if you will, about breast cancer management. And it’s always had a really good outcome,” he said.

    “It is absolutely relevant to your career. It is a really great experience if you’re already here for the conference or if you’re coming after the conference. I think if you’re interested in breast cancer and you’re interested in meeting other people in the field; this is an absolute no brainer. You should definitely come,” said Michelle.

    And why is it so important that the next generation of researchers and clinicians get involved with Breast Cancer Trials?

    As I explained to all of my patients, all the gold standard treatments that they have today were once trials. So, BCT are really the way forward for making sure that we can offer the best treatments to our patients, and we can offer the best outcomes for our patients. And as they have in their main motto, we want to make sure that there are no more lives that are cut short,” said Michelle.

    I think breast cancer clinical trials are really where we should be investing our time and our energy, and being a part of the trainee day is just one step forward on that journey. We need to have fresh minds, new thoughts, that’s we need to get change. Breast cancer management has changed so much in the last decade alone, let alone the last 60-80 years,” said Adam.

    “And it’s always been because of people thinking outside the box. And you can’t get that by the same group of people. If you don’t want stagnancy, you need to have fresh enthusiasm, new motivation, new ideas, and different ways of thinking.”

    “And all of this is really what leads to the dynamic aspect of breast cancer management. It’s what is really promoted and encouraged breast cancer clinical trials research. And we can see some absolutely incredible trials that are coming out that just really take a different mindset, a different way of thinking.”

    It’s the only way that you get that, by bringing in new people, young people, and eventually everyone retires, so we need new people to come in to take the reins and improve upon what has already been done really well. I mean, the trainees, the fellows, the early career people are the future of BCT, and it’s all about making everyone feel as included and as comfortable as possible,” he said.

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

CARING FOR THE CAREGIVERS: PREVENTING BURNOUT IN ONCOLOGY

What happens when the people caring for everyone else are running on empty? In this episode, we explore burnout of the clinician, practical self-care strategies, and ways that we can better support healthcare workers before exhaustion takes its toll. 

Caring for the Caregivers: Preventing Burnout in Oncology

What happens when the people caring for everyone else are running on empty? In this episode, we explore burnout of the clinician, practical self-care strategies, and ways that we can better support healthcare workers before exhaustion takes its toll. 

“I’m Professor Lesley Fallowfield. I’m a psycho-oncologist and I’m also director of a health outcomes research group at Brighton and Sussex Medical School in the UK.” 

“There are surveys worldwide showing that many patients are increasingly dissatisfied with the care that they get from their doctors. In particular, many report that they feel doctors lack awareness of the emotional impact that cancer has on them and act sometimes with a degree of indifference to their problems when they’re communicating with them.” 

“Now, this isn’t because doctors are bad people. Most doctors go into the profession because they care so much about the patients that they’re looking after and want to help them. But it’s precisely those doctors who care most who are liable to experience what we call in the trade, burnout, or sometimes we talk about compassion fatigue.” 

“As I said, it often affects those who start off being the most caring doctors. So, if we’re going to help patients, you need to help the carers as well, and when I’m talking about doctors, I mean nurses as well. They have worldwide a problem with burnout and compassionate fatigue. This can sort of demonstrate itself in lots of different types of ways that people can cease to get enjoyment from their work.” 

“They feel de-personalised. They don’t feel like they’re responding anymore to the sorts of things that normal human beings do. So why is this happening? Well, there’s a lot of things going on in the world. Perversely, the improvements we’ve made in cancer mean that more people are surviving, so there’s more people being treated through course in our clinics.” 

“But this is all contributing to putting pressures on doctors. Most people, when they’re sitting in a busy clinic, can see the speed at which people are having to be processed. And I use that word specifically because that’s what patients feel. They feel like they’re being processed, and that people aren’t considering that they’re ordinary human beings.” 

“So that’s one thing. I think it’s the rising numbers of patients being treated. But there are other things as well. I like to speak about the tyranny of emails. We think that all the modern technology has improved things and should help make things swifter and slicker and easier to deal with. But I mean, I don’t know what other people find, but I get about 50 emails a day and I haven’t got a busy clinic to run as well.” 

“So, there’s the tyranny of emails, the pace which people expect you to be able to respond to things. We’ve seen another interesting thing happening of late, which is that the electronic patient record should mean that it’s simpler for doctors to access all the reports and information that they need when they’re treating a patient. Unfortunately, that doesn’t always happen very smoothly.” 

“Not all our systems talk to each other, and that can lead to frustrations as well. So, there are multiple levels at which the system fails, a doctor and a nurse and a patient. But I think also we fail the most of all by not looking after their emotional needs too. You cannot expect a healthcare professional to get closer to the emotional needs of the patient, to act empathically when they’re describing sad, bad and difficult news with them if nobody gives a damn about them.” 

“And I think we need to implement many, many more systems changes, that infuse getting help for doctors. And not to be seen as someone who can’t really come, or who just has to get on with it – that’s the job. It isn’t the job. The job should be a satisfying, well paid, career that has benefits for all the doctors and nurses involved and their patients.” 

Listen to the podcast

What happens when the people caring for everyone else are running on empty? In this episode, we explore burnout of the clinician, practical self-care strategies, and ways that we can better support healthcare workers before exhaustion takes its toll.

key take away icon

Key takeaways

1. Burnout and moral injury are systemic problems, not personal failings

Professor Leslie Fallowfield highlights that many healthcare professionals — especially those who care deeply — experience burnout or compassion fatigue due to rising workloads, administrative burdens (“the tyranny of emails”), and inefficient systems. She distinguishes burnout from moral injury, where clinicians feel guilt or distress when system pressures prevent them from providing the care they believe patients deserve.


2. Emotional wellbeing of clinicians is critical to patient care

Clinicians cannot provide empathetic, high-quality care if their own emotional needs are ignored. When doctors and nurses are exhausted, depersonalised, or unsupported, patient satisfaction and safety suffer. Supporting healthcare workers’ mental health is therefore integral to good patient outcomes — not an optional extra.


3. Solutions require both personal self-care and organisational change

While individual strategies like CBT, counselling, exercise, rest, and setting boundaries (“learn to say no”) are valuable, Fallowfield stresses that real prevention depends on system-level reform — manageable clinic sizes, fewer redundant administrative tasks (“getting rid of stupid stuff”), mentoring and debriefing programs, and built-in mental-health supports as part of professional development.


4. Leadership and team culture are key buffers against burnout

Managers and team leaders must prioritise staff wellbeing as part of organisational sustainability. Strong, supportive, and well-functioning multidisciplinary teams reduce burnout risk. Communication-skills training and peer support enhance teamwork, efficiency, and resilience — creating a culture where asking for help is seen as strength, not weakness.

What are some of the key warning signs that a healthcare worker might be approaching burnout?

“There are lots of warning signs that people are approaching full blown burnout. Disillusionment with their job, frustration, that it doesn’t bring them the same sorts of pleasures that they used to experience.” 

“There’s another thing I haven’t already mentioned, which is slightly different from burnout, but that I think I see in quite a few healthcare professionals whom I speak with. And that’s moral injury.” 

“And that’s when you know that because of the pressures within the system, you’ve just not delivered the sort of care for a patient that makes you feel good and they deserve. And then people start feeling extremely guilty and you can’t enjoy a job when you know that the system is set up such that you can’t perform in the way that professionally you feel is appropriate.” 

“We hear that error rates are firing.  The retention rates within the system are sort of under threat everywhere. The loss of doctors and nurses are leaving the job precisely because it’s not that they don’t care, it’s just that they can’t care and perform their job in the way that they want. There are lots of interventions that can help prevent burnout, but you sort of alluded to require some systems changes.” 

“There are also interventions in terms of therapies like cognitive behavior therapy, counselling, relaxation. That can help enormously if you’re the sort of person who does respond to those. But I’m more interested in going back a stage and helping doctors really think far about self-care. And what I mean about that is quite simple. Remember the things they advise their patients to do. Drink less, don’t smoke, eat proper food, exercise more, sleep better and make time for holidays. Have down time with the family doing other things.” 

“We advise other people to do all this, but really some of the most committed doctors I know don’t make the same sorts of changes in their own lifestyle. And then I think if we go back to the work setting, I think it might need some really clever negotiation with management about expectations that people have on the size of clinics and the workloads that they have.” 

“I think one ought to consider also the numbers of committees and extra things you’ll serve on. 

“And I’m a dreadful culprit for this. Learn how to say no more often and at the end of the day, I always advise people that being an oncologist or a surgeon or a nurse should be what you do. It shouldn’t be who you are.” 

“It shouldn’t be just when people are absolutely on their knees, they’re begging for some help, that they get these resources. They should be there all the time. It’s almost like a professional and a managerial responsibility I think.”

How can leaders and managers better recognise and respond to the needs of their teams?

“I think all managers now have a big responsibility to consider the health of their workforce and the numbers of health professionals leaving the job is unsustainable. I mean, we’ll make it even worse for the doctors and nurses who do remain if we can’t do something about staff retention or sometimes just simply the numbers of people who just go off sick because they cannot actually cope anymore things which ultimately puts pressure on those who are left behind as it’s a vicious circle or a spiral because they too then become even more burnt out.” 

“So, from a manager’s perspective, I think there’s a clear need if they want to improve the survey reports about hospital patient satisfaction, if they want to reduce the numbers of complaints, the errors and litigation and hang on to a good, productive, happy work. For this they have to do something about looking at the organisation and implementing proper support for their doctors and nurses.” 

Are there programs or initiatives that have made a real difference in supporting staff?

“During COVID, when pressures on everyone, certainly in places like the UK, were vast and huge, it was quite clear that there needed to be some overt support for the healthcare professionals trying against all the odds to keep systems going.” 

“And we did see some sort of local initiatives that were effective at supporting people to do a most impossible job outside COVID. Some of those have continued, you know, sort of counselling, and mentoring, these sorts of things, but it becomes a problem if people don’t prioritise those, if they don’t see these sorts of supportive interventions for themselves as pivotal in maintaining their own professionals sort of work levels with patients there.” 

“There are some small local initiatives to help support healthcare professionals in a preventive situation as well as then people do have burnout, but they’re not sort of routinely available everywhere. Despite recommendations that many professional bodies have made that these sorts of things should be integral to continuing a professional development, we need to have more of them.” 

“It shouldn’t be just when people are absolutely on their knees, they’re begging for some help, that they get these resources. They should be there all the time. It’s almost like a professional and a managerial responsibility I think.” 

Is there still a stigma around healthcare workers prioritising self-care? How can this culture shift?

Times change, attitudes change, but you will still find in healthcare the few dinosaurs who you hear saying things like well if they can’t stand the heat they should get out of the kitchen’. Or in my day it was much worse, and we just got on with it. Just because somebody else managed to get through a rotten system, doesn’t mean that we should force it on others. Indeed, we have a responsibility to make their work life much better.  

“Before one really gets into full blown burnout, there are usually lots of other signs. People don’t find satisfaction in going to work, they’re depressed very often. That’s all associated with burnout, not sleeping well, not finding enjoyment in many things.”

How can healthcare organisations create an environment that better supports employee wellbeing?

“It’s a complicated issue to think about the sorts of institutional changes that are required so that the workforce is less liable to areas like burnout. It will differ of course, because different hospitals, different systems of healthcare have their own different types of pressures, but I think just making fees more efficient can help.” 

“We do a lot of rubbish things in our hospitals. There was a very interesting project conducted some time ago called the ‘Gross Initiative’. This was done in a corporate setting and gross stands for ‘getting rid of stupid stuff’, which whenever I mention it people think, oh that’s some sort of semi-psychological sort of paper.” 

“But that’s not the case. A big corporate organisation was worried about efficiency and so they asked everybody in the organisation, whatever level they were at, to complete a form saying stuff that they did that they couldn’t see the point of or that will get overturned by somebody else in another meeting.” 

“And essentially when all of these results came back, they found that lots of people were suggesting exactly the same things. No one could understand why they were still having to do this or that. And within all of our hospitals, we do have systems and forms that we have to keep filling in or interacting with the computer on, that nobody understands why we still have to do this and does it matter.” 

“So, I think first of all, getting rid of stupid stuff. It is a great idea for a manager to look at the repetitiveness of the sorts of things that get stored on the electronic record. I mean, repeatedly patients complain about being asked exactly the same questions by different healthcare providers that should be already there. Maybe checking is a good thing, but there’s too much repetition and these sorts of things are frustrating.” 

“The reason I’m going on about it is that the reason most people came into medical nursing is because they love people. They like interacting with people, they like trying to fix things for them. And if you spend most of your day interacting with a computer, other than the really nerdy ones that like that sort of stuff, what fun is there in that? And that can be a frustration as well.” 

“So, getting rid of unnecessary things is important. I think one of the things most of our organisations could do as well as implementing this, as I’ve referred to several times now, is being mandatory within any healthcare service that people have got debriefing facilities, mentoring facilities and housing facilities.” 

“We all have to do mandatory training on fire extinguishers and goodness knows whatever else, while I think you need to extinguish the fires going out with burnout.” 

What roles do peer support and team culture play in helping healthcare workers cope with stress?

“One of the things that has happened over the last couple of decades is that the delivery of cancer care now is a serious team business, and most healthcare systems have multidisciplinary tools or other variants of it now.” 

“That’s great if you work within a supportive, well-functioning team. It’s not so great if the rest of your career is going to be spent in a dysfunctional workplace. So team training can be quite important because there are plenty of studies showing that if you are lucky enough to be a member of a well-functioning supportive team, then you’re less likely to experience full blown burnout because each other, everyone supports each other.” 

“There’s another piece of evidence that I think is quite important and it’s sort of links in with multidisciplinary team working, and that is evidence that people who’ve attended well on evidence-based communication skills training programs actually are less likely to experience burnout because they know how to be more efficient with their use of time.” 

“They know how to respond more appropriately in ways that are satisfying for themselves and patient. Of course, if you can’t communicate well with other members of your team, that’s not going to yield to a well-functioning one. So, the presence of a good, well run multidisciplinary team is a high protective feature and in preventing burnout.” 

How can healthcare workers themselves advocate for better support without fear of judgement?

“Before they get really in a bad way, if there’s no obvious help available within their organisation there are some good online resources that people can access, relaxation techniques that they can learn.” 

“Most professional organisations are available to physicians. Surgeons and nurses also run self-help programs that are worth looking at. But one of the things we often find about people who are very burnt out is they’ve lost motivation to even do that. So, it’s sort of acting before you really get into those bad steaks.” 

“Working in Healthcare is such a privilege on one level, and good stress is good for you, but we want stress to burnish people, not burn them out. It’s very hard if you work with others who feel you’ve just got to be made of the right stuff and get on with it. And that does inhibit people from admitting that they’re struggling.” 

“I guess the only thing I sometimes suggest, apart from the fact that I think everyone now has a responsibility to look after people’s mental health, not just their physical health. One of the techniques I often suggest to people is that they employ the evidence base. You just look at things like litigation and error rates in people, this often shows that they are burnt out, and most hospitals want to avoid that.” 

QUICK ACCESS

profile image

Professor Dame Lesley Fallowfield

Dame Lesley Fallowfield is Professor of Psycho-oncology at Brighton & Sussex Medical School, University of Sussex where she is Director of the Sussex Health Outcomes Research & Education in Cancer (SHORE-C) group.

Support Breast Cancer Research

Caring for the Caregivers: Preventing Burnout in Oncology

What happens when the people caring for everyone else are running on empty? In this episode, we explore burnout of the clinician, practical self-care strategies, and ways that we can better support healthcare workers before exhaustion takes its toll. 

Podcast Transcript

  • Caring for the Caregivers: Preventing Burnout in Oncology

    What happens when the people caring for everyone else are running on empty? In this episode, we explore burnout of the clinician, practical self-care strategies, and ways that we can better support healthcare workers before exhaustion takes its toll. 

    “I’m Professor Lesley Fallowfield. I’m a psycho-oncologist and I’m also director of a health outcomes research group at Brighton and Sussex Medical School in the UK.” 

    “There are surveys worldwide showing that many patients are increasingly dissatisfied with the care that they get from their doctors. In particular, many report that they feel doctors lack awareness of the emotional impact that cancer has on them and act sometimes with a degree of indifference to their problems when they’re communicating with them.” 

    “Now, this isn’t because doctors are bad people. Most doctors go into the profession because they care so much about the patients that they’re looking after and want to help them. But it’s precisely those doctors who care most who are liable to experience what we call in the trade, burnout, or sometimes we talk about compassion fatigue.” 

    “As I said, it often affects those who start off being the most caring doctors. So, if we’re going to help patients, you need to help the carers as well, and when I’m talking about doctors, I mean nurses as well. They have worldwide a problem with burnout and compassionate fatigue. This can sort of demonstrate itself in lots of different types of ways that people can cease to get enjoyment from their work.”

    “They feel de-personalised. They don’t feel like they’re responding anymore to the sorts of things that normal human beings do. So why is this happening? Well, there’s a lot of things going on in the world. Perversely, the improvements we’ve made in cancer mean that more people are surviving, so there’s more people being treated through course in our clinics.” 

    “But this is all contributing to putting pressures on doctors. Most people, when they’re sitting in a busy clinic, can see the speed at which people are having to be processed. And I use that word specifically because that’s what patients feel. They feel like they’re being processed, and that people aren’t considering that they’re ordinary human beings.” 

    “So that’s one thing. I think it’s the rising numbers of patients being treated. But there are other things as well. I like to speak about the tyranny of emails. We think that all the modern technology has improved things and should help make things swifter and slicker and easier to deal with. But I mean, I don’t know what other people find, but I get about 50 emails a day and I haven’t got a busy clinic to run as well.” 

    “So, there’s the tyranny of emails, the pace which people expect you to be able to respond to things. We’ve seen another interesting thing happening of late, which is that the electronic patient record should mean that it’s simpler for doctors to access all the reports and information that they need when they’re treating a patient. Unfortunately, that doesn’t always happen very smoothly.” 

    “Not all our systems talk to each other, and that can lead to frustrations as well. So, there are multiple levels at which the system fails, a doctor and a nurse and a patient. But I think also we fail the most of all by not looking after their emotional needs too. You cannot expect a healthcare professional to get closer to the emotional needs of the patient, to act empathically when they’re describing sad, bad and difficult news with them if nobody gives a damn about them.” 

    “And I think we need to implement many, many more systems changes, that infuse getting help for doctors. And not to be seen as someone who can’t really come, or who just has to get on with it – that’s the job. It isn’t the job. The job should be a satisfying, well paid, career that has benefits for all the doctors and nurses involved and their patients.” 

    What are some of the key warning signs that a healthcare worker might be approaching burnout? 

    “There are lots of warning signs that people are approaching full blown burnout. Disillusionment with their job, frustration, that it doesn’t bring them the same sorts of pleasures that they used to experience.” 

    “There’s another thing I haven’t already mentioned, which is slightly different from burnout, but that I think I see in quite a few healthcare professionals whom I speak with. And that’s moral injury.” 

    “And that’s when you know that because of the pressures within the system, you’ve just not delivered the sort of care for a patient that makes you feel good and they deserve. And then people start feeling extremely guilty and you can’t enjoy a job when you know that the system is set up such that you can’t perform in the way that professionally you feel is appropriate.” 

    “We hear that error rates are firing.  The retention rates within the system are sort of under threat everywhere. The loss of doctors and nurses are leaving the job precisely because it’s not that they don’t care, it’s just that they can’t care and perform their job in the way that they want. There are lots of interventions that can help prevent burnout, but you sort of alluded to require some systems changes.” 

    “There are also interventions in terms of therapies like cognitive behavior therapy, counselling, relaxation. That can help enormously if you’re the sort of person who does respond to those. But I’m more interested in going back a stage and helping doctors really think far about self-care. And what I mean about that is quite simple. Remember the things they advise their patients to do. Drink less, don’t smoke, eat proper food, exercise more, sleep better and make time for holidays. Have down time with the family doing other things.” 

    “We advise other people to do all this, but really some of the most committed doctors I know don’t make the same sorts of changes in their own lifestyle. And then I think if we go back to the work setting, I think it might need some really clever negotiation with management about expectations that people have on the size of clinics and the workloads that they have.” 

    “I think one ought to consider also the numbers of committees and extra things you’ll serve on. 

    “And I’m a dreadful culprit for this. Learn how to say no more often and at the end of the day, I always advise people that being an oncologist or a surgeon or a nurse should be what you do. It shouldn’t be who you are.” 

    And how can leaders and managers better recognise and respond to the needs of their teams? 

    “I think all managers now have a big responsibility to consider the health of their workforce and the numbers of health professionals leaving the job is unsustainable. I mean, we’ll make it even worse for the doctors and nurses who do remain if we can’t do something about staff retention or sometimes just simply the numbers of people who just go off sick because they cannot actually cope anymore things which ultimately puts pressure on those who are left behind as it’s a vicious circle or a spiral because they too then become even more burnt out.” 

    “So, from a manager’s perspective, I think there’s a clear need if they want to improve the survey reports about hospital patient satisfaction, if they want to reduce the numbers of complaints, the errors and litigation and hang on to a good, productive, happy work. For this they have to do something about looking at the organisation and implementing proper support for their doctors and nurses.” 

    And are there particular programs or initiatives that you’ve seen that have made a real difference in supporting staff? 

    “During COVID, when pressures on everyone, certainly in places like the UK, were vast and huge, it was quite clear that there needed to be some overt support for the healthcare professionals trying against all the odds to keep systems going.” 

    “And we did see some sort of local initiatives that were effective at supporting people to do a most impossible job outside COVID. Some of those have continued, you know, sort of counselling, and mentoring, these sorts of things, but it becomes a problem if people don’t prioritise those, if they don’t see these sorts of supportive interventions for themselves as pivotal in maintaining their own professionals sort of work levels with patients there.” 

    “There are some small local initiatives to help support healthcare professionals in a preventive situation as well as then people do have burnout, but they’re not sort of routinely available everywhere. Despite recommendations that many professional bodies have made that these sorts of things should be integral to continuing a professional development, we need to have more of them.” 

    “It shouldn’t be just when people are absolutely on their knees, they’re begging for some help, that they get these resources. They should be there all the time. It’s almost like a professional and a managerial responsibility I think.” 

    Do you think there’s still a stigma around healthcare workers prioritising self-care? And how can that culture shift? 

    “Times change, attitudes change, but you will still find in healthcare the few dinosaurs who you hear saying things like ‘well if they can’t stand the heat they should get out of the kitchen’. Or ‘in my day it was much worse, and we just got on with it’. Just because somebody else managed to get through a rotten system, doesn’t mean that we should force it on others. Indeed, we have a responsibility to make their work life much better.  

    And how can healthcare organisations create an environment that better supports employee wellbeing? 

    “It’s a complicated issue to think about the sorts of institutional changes that are required so that the workforce is less liable to areas like burnout. It will differ of course, because different hospitals, different systems of healthcare have their own different types of pressures, but I think just making fees more efficient can help.” 

    “We do a lot of rubbish things in our hospitals. There was a very interesting project conducted some time ago called the ‘Gross Initiative’. This was done in a corporate setting and gross stands for ‘getting rid of stupid stuff’, which whenever I mention it people think, oh that’s some sort of semi-psychological sort of paper.” 

    “But that’s not the case. A big corporate organisation was worried about efficiency and so they asked everybody in the organisation, whatever level they were at, to complete a form saying stuff that they did that they couldn’t see the point of or that will get overturned by somebody else in another meeting.” 

    “And essentially when all of these results came back, they found that lots of people were suggesting exactly the same things. No one could understand why they were still having to do this or that. And within all of our hospitals, we do have systems and forms that we have to keep filling in or interacting with the computer on, that nobody understands why we still have to do this and does it matter.” 

    “So, I think first of all, getting rid of stupid stuff. It is a great idea for a manager to look at the repetitiveness of the sorts of things that get stored on the electronic record. I mean, repeatedly patients complain about being asked exactly the same questions by different healthcare providers that should be already there. Maybe checking is a good thing, but there’s too much repetition and these sorts of things are frustrating.” 

    “The reason I’m going on about it is that the reason most people came into medical nursing is because they love people. They like interacting with people, they like trying to fix things for them. And if you spend most of your day interacting with a computer, other than the really nerdy ones that like that sort of stuff, what fun is there in that? And that can be a frustration as well.” 

    “So, getting rid of unnecessary things is important. I think one of the things most of our organisations could do as well as implementing this, as I’ve referred to several times now, is being mandatory within any healthcare service that people have got debriefing facilities, mentoring facilities and housing facilities.” 

    “We all have to do mandatory training on fire extinguishers and goodness knows whatever else, while I think you need to extinguish the fires going out with burnout.” 

    What roles do peer support and team culture play in helping healthcare workers cope with stress? 

    “One of the things that has happened over the last couple of decades is that the delivery of cancer care now is a serious team business, and most healthcare systems have multidisciplinary tools or other variants of it now.” 

    “That’s great if you work within a supportive, well-functioning team. It’s not so great if the rest of your career is going to be spent in a dysfunctional workplace. So team training can be quite important because there are plenty of studies showing that if you are lucky enough to be a member of a well-functioning supportive team, then you’re less likely to experience full blown burnout because each other, everyone supports each other.” 

    “There’s another piece of evidence that I think is quite important and it’s sort of links in with multidisciplinary team working, and that is evidence that people who’ve attended well on evidence-based communication skills training programs actually are less likely to experience burnout because they know how to be more efficient with their use of time.” 

    “They know how to respond more appropriately in ways that are satisfying for themselves and patient. Of course, if you can’t communicate well with other members of your team, that’s not going to yield to a well-functioning one. So, the presence of a good, well run multidisciplinary team is a high protective feature and in preventing burnout.” 

    So how can healthcare workers themselves advocate for better support without fear of judgement or repercussions before? 

    “Before one really gets into full blown burnout, there are usually lots of other signs. People don’t find satisfaction in going to work, they’re depressed very often. That’s all associated with burnout, not sleeping well, not finding enjoyment in many things.” 

    “And before they get really in a bad way, if there’s no obvious help available within their organisation there are some good online resources that people can access, relaxation techniques that they can learn.” 

    “Most professional organisations are available to physicians. Surgeons and nurses also run self-help programs that are worth looking at. But one of the things we often find about people who are very burnt out is they’ve lost motivation to even do that. So, it’s sort of acting before you really get into those bad steaks.” 

    “Working in Healthcare is such a privilege on one level, and good stress is good for you, but we want stress to burnish people, not burn them out. It’s very hard if you work with others who feel you’ve just got to be made of the right stuff and get on with it. And that does inhibit people from admitting that they’re struggling.” 

    “I guess the only thing I sometimes suggest, apart from the fact that I think everyone now has a responsibility to look after people’s mental health, not just their physical health. One of the techniques I often suggest to people is that they employ the evidence base. You just look at things like litigation and error rates in people, this often shows that they are burnt out, and most hospitals want to avoid that.” 

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

NEOADJUVANT NOW: WHAT’S NEXT IN PRE-SURGICAL BREAST CANCER TREATMENT?

In this episode, our guest Dr Javier Cortes, Head of the International Breast Cancer Centre (IBCC) in Barcelona, shares insights into the latest neoadjuvant treatments being tested and how they could shape the future of breast cancer care.

Neoadjuvant Now: What’s Next in Pre-Surgical Breast Cancer Treatment?

More breast cancer patients are now receiving treatment before surgery, also known as neoadjuvant therapy. But what’s next for this approach?

In this episode, our guest Dr Javier Cortes, Head of the International Breast Cancer Centre (IBCC) in Barcelona, shares insights into the latest neoadjuvant treatments being tested and how they could shape the future of breast cancer care.

“Neoadjuvant therapy is giving usual systemic treatments before the final surgery to optimise long-term outcomes and also to optimise surgery. It has shown that we have a second option to treat our patients for those ones who do not achieve pathological complete remission.”

“This is one of the most important reasons to go from the adjuvant therapy in the HER2-positive setting and to relate that to other breast cancer subtypes. The adjuvant therapy has had a lot of advantages, one of them being that we cand decrease the tumour size.”

“So basically, the surgery will be much better, and I think that one of the most important aspects is to look at the pathological complete or not pathological complete information of the tumour and this will tell us the possibility to have different options after surgery.”

“Pathological complete response is a very important endpoint for patients. We know that those patients who achieve pathological complete remission will have much better outcomes. And this is a second important aspect of PCR, is that we know that for those patients who need not achieve pathological complete remission, if we go for further treatment after surgery, we will improve outcomes.”

What new drugs or treatment combinations are currently being explored in the neoadjuvant setting?

“We have more and better agents in both in the anti HER2-setting but also in the triple-negative breast cancer setting, that we have included that will locate against HER2 or HER2+ breast cancer, and we have started to use both carboplatin and immunotherapy in the triple-negative breast cancer situation.”

“More and more we have learned how to de-escalate treatment basically in HER2+ disease, which means that we can cure the same number of patients without giving so much therapy. We have seen that many patients could be cured even without the need of chemotherapy or just decreasing the amount of chemotherapy and that’s one of the most beautiful aspects.”

There are many strategies which have been explored in the new urban setting. We are exploring different immunotherapy combinations in the triple-negative breast cancer setting. We’re exploring many anterior conjugate-based therapies in the HER2+ positive and also triple-negative breast cancer settings. So many new strategies are being explored there.”

Listen to the podcast

In this episode, our guest Dr Javier Cortes, Head of the International Breast Cancer Centre (IBCC) in Barcelona, shares insights into the latest neoadjuvant treatments being tested and how they could shape the future of breast cancer care.

key take away icon

Key takeaways

1. Neoadjuvant therapy improves outcomes and guides personalised care

Giving systemic treatment before surgery helps shrink tumours, improves surgical outcomes, and—crucially—provides information about pathological complete response (PCR). PCR is a strong predictor of long-term survival and helps clinicians tailor post-surgery treatments for those who don’t achieve a full response.


2. Treatment is shifting toward precision and de-escalation

Advances in the HER2-positive and triple-negative breast cancer settings now allow many patients to be cured with less chemotherapy, or even without it. Trials like PHERGain 2 are testing chemotherapy-free regimens, while others are exploring antibody–drug conjugates and immunotherapy combinations to further individualise care.


3. Quality of life and patient choice are central

By reducing drug intensity and side effects through de-escalation, clinicians can maintain or improve quality of life without compromising cure rates. Communication with patients—especially about timing of surgery and treatment expectations—is key to managing anxiety and supporting shared decision-making.


4. The future lies in biological and genomic integration

In the next 5–10 years, genomic testing and biological profiling will play a greater role in selecting neoadjuvant therapies. This integration will help optimise treatment sequencing, avoid overtreatment, and extend neoadjuvant approaches even to earlier-stage and lower-risk breast cancers.

How has neoadjuvant therapy evolved over the past decade, and what key advances have shaped its current use?

“In the HER2+ field we are looking at new anti-viral conduits which might show improvements to pathological complete remission, but also we have many clinical trials to de-escalate treatments.”

“For example, PHERGain 2 is exploring a chemotherapy-free treatment for HER2-positive early breast cancer, using a combination of trastuzumab and pertuzumab, and we expect to have their results on this trial very soon.”

“In the triple-negative breast cancer setting we are also exploring different anti-viral conjugates in combination with immunotherapy, and we might remove the use of chemotherapy. So amazing times ahead.”

“Everything has pros and cons. Sometimes the patients know that they have a tumour. So, there is anxiety for the patients, who want to remove the tumour as soon as possible. We have to talk to them to say sometimes it’s much more important to wait and go for surgery afterwards.”

What are some of the biggest benefits of giving therapy before surgery rather than after?

“The certain aspect is that sometimes toxicity might appear and if it’s not frequent, you might delay surgery a little bit depending on those aspects. And last but not least, I think it is very unlikely to happen, but of course, maybe a minor number of patients could experience progressing disease during neoadjuvant treatment, and they should go for surgery as soon as possible.”

“These are challenges, but in my opinion, these aspects should not tell us that we do not have to use neoadjuvant therapy. I think that that’s something that we can control, something that we can manage, and something that we can avoid if needed.”

“But please think about neoadjuvant therapy in a very positive way, because this is the best way to treat our patients.”

How do patient preferences and quality of life factor into decisions about neoadjuvant treatment?

The possibility for patients to be free of disease after surgery is much higher. Usually, we’ll not have a decrease in the quality of life because usually when we are going to treat our patients, we’ll give similar drugs in the neoadjuvant versus in the adjuvant setting.”

One more important aspect is that we’ll be able to de-escalate treatment many times if we give less drugs, that will improve the quality of life.

“When we are going to say to the patient that we are going to cure, sometimes using de-escalated treatment, sometimes even without the need of surgery in the very near future. So, curing the same or more with less treatment, I think this is challenging and I think it’s great to talk to the patient and say, listen, sometimes you will not need chemotherapy. We’re explaining the de-escalating strategies.”

“In general, we have some important benefits from stage 2 and stage 3, HER2+ and triple-negative breast cancer patients. But it’s true that the treatment options after surgery gave us a higher possibility to have pathological remission and even tailored, I think that the agreement for our patient will be to be treated with a newer strategy.”

“We are facing some of the stage 1 breast cancers with neoadjuvant therapy. I think that more and more we implement different strategies with neoadjuvant treatments in patients not only with stage 2, and stage 3 cancers, but only also with stage 1 and as I said before, in patients with low-risk tumours as well.”

What are some of the ongoing challenges with neoadjuvant therapy, such as side effects, resistance or overtreatment?

“Toxicity is something to be considered, of course, and also the possibility to look at resistances in the tumours. But I think that this is something that we can observe that is so unlikely to happen and we can always go to surgery if needed.”

“And for both early breast cancer and metastatic breast cancer, in my opinion it’s even more important because at the end of the day we have to increase the quality of life. And maintaining quality of life in the early breast cancer society is of course also very important. But we should not forget that the primary objective is to cure our patients.”

“Quality of life is key, and is very important, but curing the patients is the most important endpoint when we are facing these patients. And I think that we have plenty of clinical trials which are approaching this method. So, I think that these two aspects are very important, but optimising therapy if no PCR has been achieved after surgery, it’s a very important surrogate endpoint for clinical trials.”

“I think that the new advanced setting has been clearly improved. I think all research is exciting. You know, trying to improve something, whatever it is, is terrific and amazing.”

“But I think that the more we know about the biology, the more we know about the new agents and the more we know about what these agents might offer, we will move from the metastatic to the adjuvant to the neoadjuvant setting.”

For example, in the oestrogen-positive, HER2- disease, we are facing now decent strategies to de-escalate treatments using the neoadjuvant approach. So I’m sure that in the future we will also use the neoadjuvant approach with different drugs also in less risky patient population.”

Looking ahead, what do you anticipate the next 5-10 years will look like in the neoadjuvant therapy space?

“I think that currently genomic testing is widely used in the adjuvant setting, but more and more we’re implementing all these tools also into the neoadjuvant approach.”

“Unfortunately, we will not have a clear path yet and I’m sure that in the very near future we’ll implement the best treatments with the best biological tools, and biological assessments to optimise patient care and in implementing this technology, this will help us to de-escalate and to use more treatments in the neoadjuvant setting.”

QUICK ACCESS

profile image

Dr Javier Cortes

Javier Cortes is Head of the International Breast Cancer Centre (IBCC), a medical oncologist, and considered a leading expert on HER2+ breast cancer.

Support Breast Cancer Research

Neoadjuvant Now: What’s Next in Pre-Surgical Breast Cancer Treatment?

In this episode, our guest Dr Javier Cortes, Head of the International Breast Cancer Centre (IBCC) in Barcelona, shares insights into the latest neoadjuvant treatments being tested and how they could shape the future of breast cancer care.

Podcast Transcript

  • Neoadjuvant Now: What’s Next in Pre-Surgical Breast Cancer Treatment

    More breast cancer patients are now receiving treatment before surgery, also known as neoadjuvant therapy. But what’s next for this approach?

    In this episode, our guest Dr Javier Cortes, Head of the International Breast Cancer Centre (IBCC) in Barcelona, shares insights into the latest neoadjuvant treatments being tested and how they could shape the future of breast cancer care.

    Can you explain what neoadjuvant therapy is and why it’s used in breast cancer treatment?

    “Neoadjuvant therapy is giving usual systemic treatments before the final surgery to optimise long-term outcomes and also to optimise surgery. It has shown that we have a second option to treat our patients for those ones who do not achieve pathological complete remission.”

    “This is one of the most important reasons to go from the adjuvant therapy in the HER2-positive setting and to relate that to other breast cancer subtypes. The adjuvant therapy has had a lot of advantages, one of them being that we cand decrease the tumour size.”

    “So basically, the surgery will be much better, and I think that one of the most important aspects is to look at the pathological complete or not pathological complete information of the tumour and this will tell us the possibility to have different options after surgery.”

    “Pathological complete response is a very important endpoint for patients. We know that those patients who achieve pathological complete remission will have much better outcomes. And this is a second important aspect of PCR, is that we know that for those patients who need not achieve pathological complete remission, if we go for further treatment after surgery, we will improve outcomes.”

    And what new drugs or treatment combinations are currently being explored in the neoadjuvant setting?

    “We have more and better agents in both in the anti HER2-setting but also in the triple-negative breast cancer setting, that we have included that will locate against HER2 or HER2+ breast cancer, and we have started to use both carboplatin and immunotherapy in the triple-negative breast cancer situation.”

    “More and more we have learned how to de-escalate treatment basically in HER2+ disease, which means that we can cure the same number of patients without giving so much therapy. We have seen that many patients could be cured even without the need of chemotherapy or just decreasing the amount of chemotherapy and that’s one of the most beautiful aspects.”

    There are many strategies which have been explored in the new urban setting. We are exploring different immunotherapy combinations in the triple-negative breast cancer setting. We’re exploring many anterior conjugate-based therapies in the HER2+ positive and also triple-negative breast cancer settings. So many new strategies are being explored there.”

    So how has neoadjuvant therapy evolved over the past decade, and what key advances have shaped its current use?

    “In the HER2+ field we are looking at new anti-viral conduits which might show improvements to pathological complete remission, but also we have many clinical trials to de-escalate treatments.”

    “For example, PHERGain 2 is exploring a chemotherapy-free treatment for HER2-positive early breast cancer, using a combination of trastuzumab and pertuzumab, and we expect to have their results on this trial very soon.”

    “In the triple-negative breast cancer setting we are also exploring different anti-viral conjugates in combination with immunotherapy, and we might remove the use of chemotherapy. So amazing times ahead.”

    What are some of the biggest benefits of giving therapy before surgery rather than after?

    “Everything has pros and cons. Sometimes the patients know that they have a tumour. So, there is anxiety for the patients, who want to remove the tumour as soon as possible. We have to talk to them to say sometimes it’s much more important to wait and go for surgery afterwards.”

    “The certain aspect is that sometimes toxicity might appear and if it’s not frequent, you might delay surgery a little bit depending on those aspects. And last but not least, I think it is very unlikely to happen, but of course, maybe a minor number of patients could experience progressing disease during neoadjuvant treatment, and they should go for surgery as soon as possible.”

    “These are challenges, but in my opinion, these aspects should not tell us that we do not have to use neoadjuvant therapy. I think that that’s something that we can control, something that we can manage, and something that we can avoid if needed.”

    “But please think about neoadjuvant therapy in a very positive way, because this is the best way to treat our patients.”

    How do patient preferences and quality of life factor into decisions about neoadjuvant treatment?

    The possibility for patients to be free of disease after surgery is much higher. Usually, we’ll not have a decrease in the quality of life because usually when we are going to treat our patients, we’ll give similar drugs in the neoadjuvant versus in the adjuvant setting.”

    One more important aspect is that we’ll be able to de-escalate treatment many times if we give less drugs, that will improve the quality of life.

    “When we are going to say to the patient that we are going to cure, sometimes using de-escalated treatment, sometimes even without the need of surgery in the very near future. So, curing the same or more with less treatment, I think this is challenging and I think it’s great to talk to the patient and say, listen, sometimes you will not need chemotherapy. We’re explaining the de-escalating strategies.”

    “In general, we have some important benefits from stage 2 and stage 3, HER2+ and triple-negative breast cancer patients. But it’s true that the treatment options after surgery gave us a higher possibility to have pathological remission and even tailored, I think that the agreement for our patient will be to be treated with a newer strategy.”

    “We are facing some of the stage 1 breast cancers with neoadjuvant therapy. I think that more and more we implement different strategies with neoadjuvant treatments in patients not only with stage 2, and stage 3 cancers, but only also with stage 1 and as I said before, in patients with low-risk tumours as well.”

    What are some of the ongoing challenges with neoadjuvant therapy, such as side effects, resistance or overtreatment?

    “Toxicity is something to be considered, of course, and also the possibility to look at resistances in the tumours. But I think that this is something that we can observe that is so unlikely to happen and we can always go to surgery if needed.”

    “And for both early breast cancer and metastatic breast cancer, in my opinion it’s even more important because at the end of the day we have to increase the quality of life. And maintaining quality of life in the early breast cancer society is of course also very important. But we should not forget that the primary objective is to cure our patients.”

    “Quality of life is key, and is very important, but curing the patients is the most important endpoint when we are facing these patients. And I think that we have plenty of clinical trials which are approaching this method. So, I think that these two aspects are very important, but optimising therapy if no PCR has been achieved after surgery, it’s a very important surrogate endpoint for clinical trials.”

    “I think that the new advanced setting has been clearly improved. I think all research is exciting. You know, trying to improve something, whatever it is, is terrific and amazing.”

    “But I think that the more we know about the biology, the more we know about the new agents and the more we know about what these agents might offer, we will move from the metastatic to the adjuvant to the neoadjuvant setting.”

    For example, in the oestrogen-positive, HER2- disease, we are facing now decent strategies to de-escalate treatments using the neoadjuvant approach. So I’m sure that in the future we will also use the neoadjuvant approach with different drugs also in less risky patient population.”

    Looking ahead, what do you think that the next 5 to 10 years will look like for neoadjuvant therapy and breast cancer?

    “I think that currently genomic testing is widely used in the adjuvant setting, but more and more we’re implementing all these tools also into the neoadjuvant approach.”

    “Unfortunately, we will not have a clear path yet and I’m sure that in the very near future we’ll implement the best treatments with the best biological tools, and biological assessments to optimise patient care and in implementing this technology, this will help us to de-escalate and to use more treatments in the neoadjuvant setting.”

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction

split-banner-image

INTIMACY AND INSIGHT: SEXUAL HEALTH AFTER BREAST CANCER

In this episode, Dr Belinda Yeo and Dr Virginia Baird open the conversation, sharing insights into how we can better support patients navigating intimacy, identity, and wellbeing after treatment.

Intimacy and Insight: Sexual Health After Breast Cancer

Sexual health after breast cancer is a topic too often left in the shadows, yet it profoundly effects quality of life both during and post diagnosis.

In this episode, Doctor Belinda Yeo and Doctor Virginia Baird open the conversation, sharing insights into how we can better support patients navigating intimacy, identity, and wellbeing after treatment.

“My name is Belinda, and I’m a medical oncologist and a clinician scientist in Melbourne. I work at the Austin and also at the Olivia Newton John Cancer Research Institute, and I treat breast cancer.”

“I’m Ginny (Virginia) Baird, and I’m a GP by background. I’m a trainee breast physician, and I work at the Royal Hobart Hospital, and I have a breast and menopause clinic.”

Sexual Health is an important but often overlooked aspect of breast cancer care. Can you explain why it matters so much for patients?

“We can see that it’s important because the data suggests that 90% of our patients have detrimental effects to their sexual health in the setting of their breast cancer, either because of their treatment, or because of the diagnosis,” Belinda said.

“And of course, sexual health is very complicated part of our lives. So, there are many other facets that affect sexual health. It’s like the elephant in the room.”

“I see patients in the surgical clinic, and I’ll take the opportunity to ask them about their sexual health. But it might seem totally unexpected to the patient because they think they’re just going to get the results of their recent MRI scan or their mammogram and ultrasound, and they get their clinical breast examination,” Virginia said

“So, I think Belinda really covered it well in the talk today about the sorts of issues in terms of sexual health that people will experience, but what they’re actually going to talk about is a different thing.”

“I think they’ve got physical side effects from treatment, and one obvious side effect is that if they’re on hormone treatment, they have very little oestrogen or we’re hiding the oestrogen from the body and oestrogen is a really important part of sexual health,” said Belinda.

“So things like pain on intercourse, having a low or no libido, and we’re often treating patients at the time when they’re going through or have gone through menopause, and so these are issues that may even well predate their breast cancer diagnosis.”

“And then there’s a psychological element of a cancer diagnosis. How you manage the uncertainty of that fear of recurrence that plays into our sexual health as well. So, it’s complicated.”

“And maybe because it’s so complicated, we just don’t do it very well. Doctors are very good at fixing, one thing, but when you have multiple things feeding into a problem, I think we need some help.”

“And I think often the sexual health is not just about the person in front of you, it’s their relationship with the other person or persons that they have sex with or are used to having sex with, isn’t it?”

“And how you feel in terms of your confidence in a relationship with someone affects your quality of life and you know, your sense of wellbeing,” Virginia said.

Listen to the podcast

In this episode, Dr Belinda Yeo and Dr Virginia Baird open the conversation, sharing insights into how we can better support patients navigating intimacy, identity, and wellbeing after treatment.

key take away icon

Key takeaways

1. Sexual health is a major but neglected part of breast cancer care.
Up to 90% of breast cancer patients experience sexual health problems related to treatment (e.g., hormonal changes, menopause, loss of libido, pain during intercourse) and the psychological impact of diagnosis. Despite this, it remains the “elephant in the room” — rarely discussed in routine care.

2. Both patients and clinicians find the topic difficult to raise.
Cultural norms, privacy, embarrassment, and clinician discomfort make sexual health conversations uncommon. Patients often assume these issues are unique to them or not medically relevant, while clinicians may feel undertrained or short on time to address them.

3. Responsibility should rest with clinicians to initiate the discussion.
Dr Baird and Dr Yeo stress that health professionals—not patients—should open the conversation, normalising it as a standard part of care (“I ask everyone this because most people experience it”). Even brief, empathetic check-ins can improve trust, adherence to medication, and long-term wellbeing.

4. Systemic change and training are needed to make sexual health part of standard care.
Sexual wellbeing should be embedded in medical education and multidisciplinary practice, involving oncologists, nurses, GPs, physiotherapists, and allied health professionals. Better training, resources (like My Journey, Sexual Health Australia, Cancer Council), and time allocation could make sexual health support as routine as discussions about exercise or mental health.

Do you think there are barriers that exist that might prevent patients from discussing their sexual health concerns with their health care providers?

“Well, there’s two things, I think one is that people generally feel that’s private, and therefore not something that they find it easy or comfortable to talk about, particularly in the age group we’re talking about as well,” said Virginia

“Because if you found someone in their early 20s, they might be more willing to tell you what sort of sexual activity they get up to. But the majority of people who are diagnosed with breast cancer, that’s not the case, but then I think they also do detect that doctors are uncomfortable talking about it.”

“And so, it’s potentially going to be a clunky conversation, and they’re not sure what they’re going to get out of it. So, I think that’s a massive barrier. It’s just about that both sides being able to communicate.”

“And I think if they feel they have to bring it up, rather than someone asking them, they’re probably thinking, well, maybe this is just me and no one’s mentioned this to me. It’s not written down anywhere. And so, maybe this is a problem that I’ll just have to deal with myself,” Belinda said.

“And that’s what the data suggests is that most patients are managing these problems themselves. But there is help out there.”

“And I think you don’t need to be in a sexual relationship to have, sexual health needs, of course. And sometimes we make assumptions there if our patients are not partnered or not sexually active. But I think that’s wrong, and these are difficult issues for anyone to talk about, but it doesn’t mean we shouldn’t try.”

If a patient was experiencing these difficulties, what would you recommend to them? How would they initiate this conversation?

“I wouldn’t recommend that they initiate it because I think that’s not going to happen. So, I think it’s about the healthcare providers, or whoever it is to be able to bring it up and feel confident about bringing up the issue,” Virginia said.

“It’s about checking in and saying this is something I ask everyone because the majority of people going through treatment are going to be experiencing some sort of sexual health concern. So, is that something that you’re happy to talk about with me? Let’s have a conversation and see if there’s anything we can do to make you feel better.

“You may not have the answer to their problem and that’s ok, these conversations are ongoing. These problems are going to be ongoing for years. And you have to read the room a bit, and on the first consultation, when someone’s meets me, I don’t think it’s appropriate for me to give them the sexual health questionnaire to fill out, because they’ve never met me,” said Belinda.

“But you know, I think you need to get to know your patient and there’s a team involved here. It’s not just one person’s role, but if everybody thinks someone else is going to do it, it’ll never get done.”

And coming back to it, we have short consultations with our patients. One of the biggest frustrations with our patients is we have no time to go through everything. And it’s really easy just to focus on, their treatment, you know, how is the tablet going?”

“Because my focus is that they must be taking the tablet, and you think that if we go into other things, maybe that’ll lessen their adherence to the medication. But actually, if you broach side effects of treatments and try to address them as best you can, there’s actually data to suggest that adherence goes up.”

“If you use the My Journey app, there’s information through there, and they offer all kinds of resources for people to talk to about. I think Sexual Health Australia is another group as well that are online, and they’ve got information. Cancer Council too, so there’s quite a few resources available.”

What changes would you both like to see in clinical practice and research to better support he sexual health of breast cancer patients.

“This is outside of breast cancer as well, but in medical oncology training, nobody teaches you this kind of thing. And it shouldn’t be part of our training because as we saw today, like most patients who are diagnosed with cancer, it can have substantial effects on their sexual health,” Belinda said.

“And if the only way you kind of plod through this is to treat more and more patients and start to understand and read the literature, that’s probably the wrong way around. So, I think it should be in training and even if it’s in medical school, that’s a long way, before you end up becoming a specialist in in the area.”

“So, and I think the training should be with lots of different professionals. This is not just the oncologist or the surgeon or the breast care nurse, but I think it’s important to have the physios in there, have OTS in there and things like that.”

“I think when I did that National Certificate of Sexual Reproductive Health, that introduced me to resources about opening the conversation about sex with people, such as who is it you’re having sex with, how many people you have sex with, how do you have sex, just in terms of habits and things like that,” Virginia said.

But that’s only because I did that specific training, but there are still some resources available on the Melbourne Sexual Health Centre website, for example. There’ll be information on there for practitioners. But I think Belinda also touched on this earlier that there are resources in terms of staffing and personnel who have got time to address these things.”

“And also choosing who in that team is going to be the one to initiate this discussion. But I don’t think it can be just down to one person because I think if more people are asking, then it shows how important sexuality is and sexual health is as part of someone’s overall wellbeing.”

“Because we talk a lot about mental health, anxiety, depression, stress, because a lot of people in the world are experiencing that, not just people with breast cancer, but your sexual wellbeing is another part of you that’s just as important as everything else.”

“That’s so true. I think that as an example, everyone is on the bandwagon of exercise now. You come in with a breast cancer diagnosis and we’re like ‘do you exercise, you need to exercise’. And this is probably the next revolution we need within cancer treatment,” said Belinda.

QUICK ACCESS

profile image

Dr Belinda Yeo

Dr Belinda Yeo is a passionate clinician whose research focuses on finding better ways to estimate recurrence risk in breast cancer patients.
profile image

Dr Virginia Baird

Dr Virginia Baird is a GP with a specific interest in Women’s health, particularly Breast Medicine and Perimenopause/Menopause.

BUY THE DIARY THAT
SAVES LIVES

Intimacy and Insight: Sexual Health After Breast Cancer

Early Diagnosis & Improved Treatments Improve Outcomes | Breast Cancer TrialsIn this episode, Dr Belinda Yeo and Dr Virginia Baird open the conversation, sharing insights into how we can better support patients navigating intimacy, identity, and wellbeing after treatment.

Podcast Transcript

  • Choosing Your Path and Navigating Difficult Treatment Decisions

    Sexual health after breast cancer is a topic too often left in the shadows, yet it profoundly effects quality of life both during and post diagnosis.

    In this episode, Doctor Belinda Yeo and Doctor Virginia Baird open the conversation, sharing insights into how we can better support patients navigating intimacy, identity, and wellbeing after treatment.

    “My name is Belinda, and I’m a medical oncologist and a clinician scientist in Melbourne. I work at the Austin and also at the Olivia Newton John Cancer Research Institute, and I treat breast cancer.”

    “I’m Ginny (Virginia) Baird, and I’m a GP by background. I’m a trainee breast physician, and I work at the Royal Hobart Hospital, and I have a breast and menopause clinic.”

    Sexual health is an important but often overlooked aspect of Breast Cancer Care. Can you explain why it matters so much for patients?

    “We can see that it’s important because the data suggests that 90% of our patients have detrimental effects to their sexual health in the setting of their breast cancer, either because of their treatment, or because of the diagnosis,” Belinda said.

    “And of course, sexual health is very complicated part of our lives. So, there are many other facets that affect sexual health. It’s like the elephant in the room.”

    What kinds of sexual health issues do breast cancer patients commonly face during and after their treatment?

    “I see patients in the surgical clinic, and I’ll take the opportunity to ask them about their sexual health. But it might seem totally unexpected to the patient because they think they’re just going to get the results of their recent MRI scan or their mammogram and ultrasound, and they get their clinical breast examination,” Virginia said

    “So, I think Belinda really covered it well in the talk today about the sorts of issues in terms of sexual health that people will experience, but what they’re actually going to talk about is a different thing.”

    “I think they’ve got physical side effects from treatment, and one obvious side effect is that if they’re on hormone treatment, they have very little oestrogen or we’re hiding the oestrogen from the body and oestrogen is a really important part of sexual health,” said Belinda.

    “So things like pain on intercourse, having a low or no libido, and we’re often treating patients at the time when they’re going through or have gone through menopause, and so these are issues that may even well predate their breast cancer diagnosis.”

    “And then there’s a psychological element of a cancer diagnosis. How you manage the uncertainty of that fear of recurrence that plays into our sexual health as well. So, it’s complicated.”

    “And maybe because it’s so complicated, we just don’t do it very well. Doctors are very good at fixing, one thing, but when you have multiple things feeding into a problem, I think we need some help.”

    “And I think often the sexual health is not just about the person in front of you, it’s their relationship with the other person or persons that they have sex with or are used to having sex with, isn’t it?”

    “And how you feel in terms of your confidence in a relationship with someone affects your quality of life and you know, your sense of wellbeing,” Virginia said.

    “And I think you don’t need to be in a sexual relationship to have, sexual health needs, of course. And sometimes we make assumptions there if our patients are not partnered or not sexually active. But I think that’s wrong, and these are difficult issues for anyone to talk about, but it doesn’t mean we shouldn’t try,” said Belinda.

    Do you think there are barriers that exist that might prevent patients from discussing their health, sexual health concerns with their health care providers?

    “Well, there’s two things, I think one is that people generally feel that’s private, and therefore not something that they find it easy or comfortable to talk about, particularly in the age group we’re talking about as well,” said Virginia

    “Because if you found someone in their early 20s, they might be more willing to tell you what sort of sexual activity they get up to. But the majority of people who are diagnosed with breast cancer, that’s not the case, but then I think they also do detect that doctors are uncomfortable talking about it.”

    “And so, it’s potentially going to be a clunky conversation, and they’re not sure what they’re going to get out of it. So, I think that’s a massive barrier. It’s just about that both sides being able to communicate.”

    “And I think if they feel they have to bring it up, rather than someone asking them, they’re probably thinking, well, maybe this is just me and no one’s mentioned this to me. It’s not written down anywhere. And so, maybe this is a problem that I’ll just have to deal with myself,” Belinda said.

    “And that’s what the data suggests is that most patients are managing these problems themselves. But there is help out there.”

    So, if a patient came in and they were experiencing these difficulties, what would you recommend to them? How would they initiate that conversation with their healthcare provider?

    “I wouldn’t recommend that they initiate it because I think that’s not going to happen. So, I think it’s about the healthcare providers, or whoever it is to be able to bring it up and feel confident about bringing up the issue,” Virginia said.

    “It’s about checking in and saying this is something I ask everyone because the majority of people going through treatment are going to be experiencing some sort of sexual health concern. So, is that something that you’re happy to talk about with me? Let’s have a conversation and see if there’s anything we can do to make you feel better.

    “You may not have the answer to their problem and that’s ok, these conversations are ongoing. These problems are going to be ongoing for years. And you have to read the room a bit, and on the first consultation, when someone’s meets me, I don’t think it’s appropriate for me to give them the sexual health questionnaire to fill out, because they’ve never met me,” said Belinda.

    “But you know, I think you need to get to know your patient and there’s a team involved here. It’s not just one person’s role, but if everybody thinks someone else is going to do it, it’ll never get done.”

    And coming back to it, we have short consultations with our patients. One of the biggest frustrations with our patients is we have no time to go through everything. And it’s really easy just to focus on, their treatment, you know, how is the tablet going?”

    “Because my focus is that they must be taking the tablet, and you think that if we go into other things, maybe that’ll lessen their adherence to the medication. But actually, if you broach side effects of treatments and try to address them as best you can, there’s actually data to suggest that adherence goes up.”

    And are there different support networks in place for breast cancer patients who are going through these sorts of things?

    “If you use the My Journey app, there’s information through there, and they offer all kinds of resources for people to talk to about. I think Sexual Health Australia is another group as well that are online, and they’ve got information. Cancer Council too, so there’s quite a few resources available,” said Virginia.

    What changes would you both like to see in clinical practice and research to better to support the sexual health of breast cancer patients?

    “This is outside of breast cancer as well, but in medical oncology training, nobody teaches you this kind of thing. And it shouldn’t be part of our training because as we saw today, like most patients who are diagnosed with cancer, it can have substantial effects on their sexual health,” Belinda said.

    “And if the only way you kind of plod through this is to treat more and more patients and start to understand and read the literature, that’s probably the wrong way around. So, I think it should be in training and even if it’s in medical school, that’s a long way, before you end up becoming a specialist in in the area.”

    “So, and I think the training should be with lots of different professionals. This is not just the oncologist or the surgeon or the breast care nurse, but I think it’s important to have the physios in there, have OTS in there and things like that.”

    “I think when I did that National Certificate of Sexual Reproductive Health, that introduced me to resources about opening the conversation about sex with people, such as who is it you’re having sex with, how many people you have sex with, how do you have sex, just in terms of habits and things like that,” Virginia said.

    But that’s only because I did that specific training, but there are still some resources available on the Melbourne Sexual Health Centre website, for example. There’ll be information on there for practitioners. But I think Belinda also touched on this earlier that there are resources in terms of staffing and personnel who have got time to address these things.”

    “And also choosing who in that team is going to be the one to initiate this discussion. But I don’t think it can be just down to one person because I think if more people are asking, then it shows how important sexuality is and sexual health is as part of someone’s overall wellbeing.”

    “Because we talk a lot about mental health, anxiety, depression, stress, because a lot of people in the world are experiencing that, not just people with breast cancer, but your sexual wellbeing is another part of you that’s just as important as everything else.”

    “That’s so true. I think that as an example, everyone is on the bandwagon of exercise now. You come in with a breast cancer diagnosis and we’re like ‘do you exercise, you need to exercise’. And this is probably the next revolution we need within cancer treatment,” said Belinda.

Latest Articles

mastectomy recovery

Mastectomy Recovery

mastectomy: types and reconstruction

Mastectomy: Types and Reconstruction